Current trends in drug metabolism and pharmacokinetics. by Li, Yuhua et al.
UC Davis
UC Davis Previously Published Works
Title
Current trends in drug metabolism and pharmacokinetics.
Permalink
https://escholarship.org/uc/item/4qm8f0vf
Journal
Acta pharmaceutica Sinica. B, 9(6)
ISSN
2211-3835
Authors
Li, Yuhua
Meng, Qiang
Yang, Mengbi
et al.
Publication Date
2019-11-01
DOI
10.1016/j.apsb.2019.10.001
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Acta Pharmaceutica Sinica B 2019;9(6):1113e1144Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
www.elsevier.com/ loca te /apsb
www.sc iencedi rec t .comANNUAL REVIEWCurrent trends in drug metabolism and
pharmacokineticsYuhua Lia,b,y, Qiang Mengc,y, Mengbi Yangd,y, Dongyang Liue,y,
Xiangyu Houf,y, Lan Tangg,y, Xin Wangh,y, Yuanfeng Lyud,
Xiaoyan Chenf,*, Kexin Liuc,*, Ai-Ming Yui,*, Zhong Zuod,*,
Huichang Bia,*aSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510275, China
bThe First Affiliated Hospital of Nanchang University, Nanchang 330006, China
cCollege of Pharmacy, Dalian Medical University, Dalian 116044, China
dSchool of Pharmacy, the Chinese University of Hong Kong, Hong Kong, China
eDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
fShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
gSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
hSchool of Life Sciences, East China Normal University, Shanghai 200241, China
iUC Davis School of Medicine, Sacramento, CA 95817, USAReceived 7 April 2019; received in revised form 23 August 2019; accepted 9 September 2019KEY WORDS
Pharmacokinetics;
Drug metabolism;
Drugedrug interactions;
Modeling;
Metabolizing enzymes;
Transporters;
Nuclear receptors;
Noncoding RNAs*C
E-
(Zhon
yTh
Peer
https:
2211-
by Elorresponding authors. Tel.: þ86 20 3
mail addresses: xychen@simm.ac.cn
g Zuo), bihchang@mail.sysu.edu.cn
ese authors made equal contribution
review under responsibility of Institu
//doi.org/10.1016/j.apsb.2019.10.001
3835 ª 2019 Chinese Pharmaceutic
sevier B.V. This is an open access aAbstract Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion
(ADME) processes of a drug. Understanding PK properties is essential for drug development and precision
medication. In this review we provided an overview of recent research on PK with focus on the following
aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well
as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing
new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in
inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drugedrug inter-
actions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and
microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly
changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical
modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-9943470; fax: þ86 20 39943000.
(Xiaoyan Chen), liukexin89@163.com (Kexin Liu), aimyu@ucdavis.edu (Ai-Ming Yu), joanzuo@cuhk.edu.hk
(Huichang Bi).
s to this work.
te of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
al Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1114 Yuhua Li et al.based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the
involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on
future directions are discussed, and may stimulate the development of new research models, technologies,
and strategies towards the development of better drugs and improved clinical practice.
ª 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pharmacokinetics (PK) is defined as the quantitative study of drug
absorption, distribution, metabolism, and excretion (ADME)d
i.e., the ways the body processes a drug1 while the drug exerts its
actions in the body. The scope of PK not only covers studies on
healthy subjects but also includes broad research on variations
under a variety of physiologic or pathologic conditions and the
underlying mechanisms, potential drugedrug interactions (DDI),
and possible strategies such as dose adjustment to achieve preci-
sion medication. Collectively, these aspects of PK allow custom-
ization of drug dosage regimens to enhance therapeutic
outcomes1. Therefore, PK study is a prerequisite to establish the
relations and the underlying mechanisms of a drug to its activities
and clinical benefits. The information obtained is crucial for lead
identification and optimization in drug discovery, as well as
dosage regimen design and adjustment in clinical practice2. The
complexity of PK has evolved, largely in relation to the rapid
developments in analytical chemistry, computer science, molec-
ular biology and biochemistry. Although much is known with
regard to the PK of many drugs, and many technologies have been
established for PK research, recent studies are revealing the ex-
istence of new mechanisms by which how drugs are metabolized
and how PK is regulated. New experimental models and compu-
tational modeling algorithms are arising for an improved under-
standing of the significance of PK in a whole-body system;
nonetheless, many challenges remain.
This review will provide a comprehensive overview of recent
developments in the areas of PK research. First, we will provide an
update of findings on drug-metabolizing enzymes and transporters
in the control of PK, as well as advances in nuclear receptors and
noncoding RNAs (ncRNAs) in the modulation of PK, which will
provide new insights into understanding the transcriptional and
posttranscriptional regulatory mechanisms behind inter-individual
variations in pharmacotherapy. Second, we will review the current
status and trends in assessing DDIs, especially the interactions
between drugs and herbs, between drugs and therapeutic bi-
ologics, and microbiota-mediated DDIs and HDIs. Third, we will
summarize recent advances in diseaseedrug interactions, in
particular, regulation of metabolizing enzymes and transporters
and alteration of PK by different diseases or physiological states.
Fourth, we will summarize the trends in mathematical modeling
including physiologically-based PK, which could be applied to
support clinical investigations. In addition, we will discuss novel
animal models such as CRISPR/Cas9-based animal models for
DMPK research and overview some interesting non-classical
biotransformation pathways including those utilizing novel drug-
metabolizing enzymes. Existing challenges and future perspec-
tives are also discussed. It is expected that this review will providean update on recent advances in PK fields and may stimulate the
establishment of new research models, technologies, and strate-
gies towards the development of better drugs and improvements in
clinical practice.2. Determinants of PK
Drug-metabolizing enzymes and transporters play a very impor-
tant role in the control of PK. Furthermore, transcriptional and
posttranscriptional factors such as nuclear receptors and non-
coding RNAs (ncRNAs) are critical in the modulation of PK and
provide in-depth insight into understanding regulatory mecha-
nisms to solve problems in PK. These mechanism-driven PK
studies can improve the success of drug development related to its
efficacy and safety and improve the rational use of medication in
clinical practice.2.1. Drug-metabolizing enzymes in the control of PK
Drug-metabolizing enzymes mediate the metabolism of exoge-
nous and endogenous substances. Most drugs lose their pharma-
cological activities mainly through metabolic transformation,
yielding metabolites with high water solubility that are readily
excreted. Hence, metabolizing enzymes play an extremely
important role in the control of drug PK. The biotransformation of
xenobiotics by xenobiotic-metabolizing enzymes (XMEs) may be
classified into Phase I and Phase II reactions. Advanced charac-
terizations of enzymes involved in human drug metabolism are
urgently needed, which help to avoid severe adverse drug re-
actions. Advances are being made in understanding the role of
drug-metabolizing enzymes in the control of PK, including indi-
vidual isoforms of many enzymes such as cytochrome P450s
(CYPs) and UGTs, and their selective substrates, inducers and
inhibitors. Other non-P450 oxidative enzymes and conjugative
enzymes are also discussed in this section since an increasing
number of drugs are metabolized via these enzymes3.2.1.1. CYPs critical for PK
CYPs can oxidize foreign substances, enhance the water solubility
and make drugs easier to be eliminated from the body. Most drugs
are metabolized by CYPs, which mainly are located in the inner
membrane of mitochondria or the endoplasmic reticulum of cells4.
There are a total of 57 human CYP genes in 18 families. The
members of CYP1 to CYP4 families oxidize thousands of exog-
enous and endogenous substrates (Table 1); whereas all members
of CYP5 family and higher principally metabolize endogenous
substrates in a highly substrate-specific manner5.
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and polycyclic aromatic hydrocarbons (PAHs), are substrates of
CYP1 family, and their metabolism often results in the formation
of active carcinogenic metabolites. In 2018, CYP1B1 was found
in the mitochondria of cancer cells, where it reportedly metabo-
lizes melatonin to form the metabolite N-acetylserotonin (NAS),
which has antitumor effects6. CYP2D6, another important meta-
bolic enzyme, is involved in the metabolism of many anti-cancer
drugs, such as cyclophosphamide, tamoxifen, and gefitinib7.
Recent research has found that in brain, CYP2D6 can metabolize
both m-tyramine and p-tyramine into dopamine8. The CYP4
family has gained increasing attention for its potential to generate
interesting metabolites and dispose of endogenous substrates in
recent years. CYP4F11, together with CYP4F2, plays an impor-
tant role in the synthesis of 20-hydroxyeicosatetraenoic acid (20-
HETE) from arachidonic acid, and participates in the metabolism
of vitamin K9. Cyp2a5, the mouse correlate of human CYP2A6,
encodes an enzyme that exhibited circadian regulation10. The
other CYP1 to CYP4 subfamilies are involved in metabolism of
different endogenous and exogenous substrates, as listed in Table
1.
Understanding variation in mechanism-based enzyme activity is
crucial for improving the clinical use of drugs. Highly selective
inducers and inhibitors of CYPs have been cited in Guidance for
Industry by FDA (https://www.fda.gov/drugs/drug-interactions-
labeling/drug-development-and-drug-interactions-table-substrates-
inhibitors-and-inducers). Recent studies have revealed new chem-
icals and herb products as inducers or inhibitors of CYPs. For
example, CYP7A1 is upregulated by an intestinal HIF-2a inhibitor
called PT238517. The ketene intermediate of erlotinib can inactivate
CYP3A4 andCYP3A5, which can result in liver injury18. Due to the
complexity of components in the extract of herbs it is common that
herb products exhibit different effects on the regulation of multiple
enzymes. Sophora flavescens can inhibit CYP2B6, CYP2C8,
CYP2C9, and CYP3A activities, while catalpol can inhibit the ac-
tivity of CYP3A4, CYP2E1 and CYP2C919,20. Other regulatory
factors can also alter the expression of CYPs. For example, tumor
suppressor p53 can regulateCyp2b10 directly and thereby attenuate
APAP-induced hepatotoxicity21.
Herbs may be used singly or in combination in the treatment of
diseases22. It is very important to understand how drug exposure
alters molecular mechanisms underlying many complex drug in-
teractions. For example, data show that ellagic acid from pome-
granate peel guava leaf extract can significantly increase the AUC
of warfarin with concomitant use. A significant reduction in
CYP2C8, 2C9, and 3A4 activity was the main reason for this
interaction23.
Based on recently available data, new information on the relative
content of individual isoforms of P450 has been generated. Total
CYP concentrations are significantly different between Chinese and
Caucasian populations and the metabolic capabilities of CYPs in
Chinese liver microsomes was significantly lower (<50%) in the
CLint for substrates of CYP1A2, CYP2C9, CYP2C19 and CYP2E1
than those of Caucasian populations24. Large variations in protein
content, mRNA levels, and intrinsic activities of ten P450s
(CYP3A4, 1A2, etc) have been revealed and some single nucleotide
polymorphisms had significant impact on P450 expression; for
example, CYP2C19 activity varied more than 600-fold25. A recent
human PK study further evaluated CYP1A2 content in Chinese
compared with Caucasian populations, enhancing the confidence in
pharmacokinetic prediction of CYP1A2 content using two sub-
strates (caffeine and theophylline)26.Other organs like kidney and intestine also have significant
metabolic capacity. There is definitive evidence for CYP2B6 and
3A5 expression in human kidney, while multiple CYPs are
expressed in intestine27,28. The role of renal and intestinal en-
zymes in herbal product metabolism has been uncovered. Ami-
noglycoside antibiotics are leading causes for nephrotoxicity;
combination with herbs or dietary supplements at reduced dosage
is possible to reduce the risk of drug-mediated renal toxicity. A
recent study revealed that moringa oleifera seed oil could limit
gentamicin-induced oxidative nephrotoxicity29. Additional herbs
have been identified as having effects on intestinal metabolism,
such as the extracts of Yin-Chen-Hao Tang (YCHT), a very
popular hepatoprotective three-herb formula in China and Japan30.
These findings contribute to the understanding of the metabolic
characteristics of renal and intestinal metabolism.
2.1.2. Non-P450 oxidative enzymes
The contribution of non-P450 enzymes to drug metabolism can be
significant and affect the overall development of drugs. Non-CYP
enzymes can be divided into four general categories: namely
oxidative, reductive, conjugative, and hydrolytic. Non-CYP
oxidative enzymes include flavin-containing monooxygenases
(FMOs), monoamine oxidases (MAOs), peroxidases, xanthine
oxidases (XO), aldehyde oxidase (AO), alcohol dehydrogenase
(ADHs) and aldehyde dehydrogenase (ALDHs)31.
Very little is known about the regulation of content and activity of
non-P450 oxidative enzymes. Recently, some selective substrates and
inhibitors of non-P450 enzymes have been identified in natural
products and other sources. FMOs are involved in themetabolismof a
wide array of xenobiotics. Well-known inhibitors of FMOs include
indole-3-carbinol andmethimazole, and 2-mercaptobenzimidazole32.
Classified into two different isoforms (MAO-A,MAO-B), MAOs are
enzymes involved in the catabolism of monoamines. Benextramine
and its derivatives were identified as novel human monoamine oxi-
dases inhibitors, which could be considered as candidate drugs for the
treatment of neurodegenerative diseases33. In addition, 3-(3-(dime-
thylamino)propanoyl)-7-hydroxy-5-methyl-2H-chromen-2-one hyd-
rochloride has been found to function as a novel selective hMAO-B
inhibitor, which is expected to be a promising multifunctional Par-
kinson’s disease treatment agent34. XO and AO are involved in the
oxidation of aldehydes and heterocycles, and carbazeran was used as
a selective probe substrate of AO in hepatocytes35. Allopurinol and S-
allyl cysteine (SAC) are XO inhibitors used in the treatment of gout
and hyperuricemia36. A single-nucleotide polymorphism of human
cytochrome P450 oxidoreductase (POR) in the Chinese population
can regulate the content of POR and P450 isoforms37. Identifying
specific inhibitor compounds will greatly facilitate investigation of
enzyme-mediated drug disposition and drug interactions.
2.1.3. Importance of UDP-glucuronyltransferases (UGTs) in PK
UDP-glucuronyltransferases (UGTs) are a family of endoplasmic
reticulum-bound enzymes which are responsible for the process of
glucuronidation, a major part of phase II metabolism38. Human
UGTs include 22 different functional enzymes and are classified
into four gene families, UGT1, UGT2, UGT3 and UGT839. The
UGT1 and UGT2 families are primarily enzymes involved in drug
glucuronidation, while the contribution of the UGT3 and UGT8
families to drug metabolism is minimal40.
Recently, UGT1A3 was found to be involved in the glucur-
onidation of alpinetin41. UGT1A4 is involved in the glucur-
onidation of metizolam42. Other UGT isoforms involved
endogenous and exogenous substrates are listed in Table 223,43e46.
Table 1 Endogenous and exogenous substrates of CYPs and ligands of transcription factors.
Family Enzyme Endogenous substrate Xenobiotic substrate Transcription factor
CYP1 CYP1A1 Steroid (especially estrogen), aromatic
amines, polycyclic aromatic
hydrocarbons
Benzo[a]pyrene AhR
CAR
CYP1A2 Phenacetin11 AhR, CAR
CYP1B1 Steroid (especially estrogen), melatonin6 Aromatic amines, polycyclic aromatic
hydrocarbons
AhR
CYP2 CYP2A6 Steroid Nicotine, cotinine, coumarin12,13 PXR, NFE2L2, ER, GR, PXR,
HNF4a
CYP2A13 Unknown Nicotine, coumarin, 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK)14,
naphthalene15
FOXA2
CYP2B6 Synthesis of cholesterol, steroids and
other lipids.
Bupropion11, efavirenz CAR, PXR, HNF4a
CYP2C8 Arachidonic acid16 Paclitaxela, repaglinide, AZD9496, Taxol CAR, PXR, ROR, VDR
CYP2C9 Serotonin, polyunsaturated fatty acids,
arachidonic acid.
Warfarin, phenytoin, tolbutamide PXR, CAR, VDR, HNF4a
CYP2C18 Arachidonic acid, linoleic acid,
docosahexaenoic acid (DHA),
Eicosapentaenoic acid (EPA).
Tolbutamide, cyclophosphamide, ifosfamide Unknown
CYP2C19 Arachidonic acid S-Mephenytoin PXR, CAR, FOXA3
CYP2D6 Hydroxytryptamines, neurosteroids, m-
tyramine, p-tyramine8
Tamoxifen, gefitinib, cyclophosphamide,
bufuralol
HNF4a
CYP2E1 Arachidonic acid Chlorzoxazone (CHZ), acetaminophen LXR, HNF1a, NRF2
CYP2F1 3-Methylindole (3MI) Naphthalene, benzene, 1,1-dichloroethylene Unknown
CYP2J2 Arachidonic acid, vitamin D3 Astemizole Unknown
CYP2R1 Vitamin D3 Unknown Unknown
CYP2S1 Prostaglandin G(2)/H(2), thromboxane
A(2), oxygenated eicosanoids
Benzo[a]pyrene-7,8-diol Unknown
CYP2U1 Arachidonic acid, docosahexaenoic acid
(DHA)
Debrisoquin sulfate Unknown
CYP2W1 Fatty acids, lysophospholipids,retinoic
acid
Canduocarmycin Unknown
CYP3 CYP3A4 Steroid (including testosterone), vitamin
D3
Midazolam, rivaroxaban, 3-acetyl-11-keto-
b-boswellic acid (AKBA)
CAR, PXR, FXR, HNF4a, LXR,
VDR
CYP3A5 Steroid (including testosterone),
progesterone, Rostenedione
Diltiazem, cyclosporine, 3-acetyl-11-keto-b-
boswellic acid (AKBA)
PXR, LXR, HNF4a
CYP3A7 Steroid (including testosterone) 3-acetyl-11-keto-b-boswellic acid (AKBA) Glucocorticoid receptor (GR), PXR
CYP3A43 Androgen Alprazolam Unknown
CYP4 CYP4A11
CYP4A22
Arachidonic acid, fatty acid, lauric acid Unknown PPARa
CYP4B1 Furan pro-toxin 4-ipomeanol Pneumotoxin, 4-ipomeanol, aromatic
amines, 2-aminofluorene
Unknown
CYP4F2 Arachidonic acid, vitamin K
menaquinone, leukotrienes,
prostaglandins
Pafuramidine, fingolimod Unknown
CYP4F3 Arachidonic acid, prostaglandins,
leukotriene-B4
Pafuramidine Unknown
CYP4F8 Arachidonic acid, prostaglandins,
eicosanoids, dihomo-g-linolenic acid,
leukotrienes, 19-hydroxylase of
prostaglandin endoperoxides (PGEs)
Unknown Unknown
CYP4F11 Arachidonic acid, vitamin K
menaquinone9, prostaglandins,
leukotrienes
Benzphetamine, ethylmorphine,
chlorpromazine, imipramine,
erythromycin
RXR
CYP4F12 Arachidonic acid, docosahexaenoic and
eicosapentaenoic acids,
prostaglandins, leukotrienes
Ebastine, terfenadine PXR
CYP4F22 Arachidonic acid, eicosanoids,
prostaglandins, leukotrienes
Unknown Unknown
CYP4V2 Medium chain fatty acids Unknown PPARg
CYP4X1 Arachidonic acid, anandamide Unknown PPARa
CYP4Z1 Lauric acid, myristic acid Unknown Unknown
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have been found in natural products and from other sources.
Resveratrol can activate UGT1A8 expression, and is used for
breast cancer treatment47. Different doses of emodin can inhibit
the activity of UGT2B748.
In some cases, herbal products are metabolized by multiple
UGTs. Linoleic acid and glutaric acid can inhibit the glucur-
onidation of berberrubine, a lipid-lowing metabolite of berberine,
as well as the activities of UGT isoforms, such as UGT1A7, 1A8,
1A949. Glucuronidation of catalposide, an active component of
Veronica species, was catalyzed by gastro-intestine-specific UGTs
1A8 and 1A1050.
Gene polymorphisms are a key factor in the regulation of the
content and activity of UGTs. UGT1A and UGT2B genetic vari-
ation can alter nicotine and nitrosamine glucuronidation in Eu-
ropean and African American smokers51. In addition, the
UGT1A4*3 genetic polymorphism is associated with low pos-
aconazole plasma concentrations in patients with hematological
malignancies52. UGT1A1*6 polymorphisms are correlated with
irinotecan-induced neutropenia in cancer patients53.
2.1.4. Other conjugative enzymes important for PK studies
In addition to UGTs, sulfonyl transferases (SULTs) and gluta-
thione S-transferases (GSTs) are also important conjugative en-
zymes mediating phase II reaction.
SULTs catalyze the transfer of the water-soluble sulfonate
group from 30-phosphoadenosine 50-phosphosulfate to drugs or
endogenous molecules that contain hydroxy or amine group(s)54.
At present, four families of human SULTs have been discovered,
namely SULT1, SULT2, SULT4 and SULT6. SULT1E1 plays an
important role in the metabolism and detoxification of estrogens
and flavonoids55. SULT2 enzymes, mainly SULT2A and SULT2B,
are primarily responsible for catalyzing the sulfation of hydrox-
ysteroids56. A recent study found that tumor suppressor p53 could
regulate the expression of SULTs57.
GSTs are a group of phase II drug-metabolizing enzymes that
catalyze the binding of glutathione to various electrophilic com-
pounds. In humans, cytosolic GST isoenzymes of the alpha, zeta,
theta, mu, pi, sigma and omega classes have been found. GSTA1
plays a significant role in the metabolism of acetaminophen58.
GSTA4 metabolizes electrophilic and carcinogenic substances
such as endogenous carcinogen 4-hydroxy-2-nonenal59. The
detailed substrates of SULTs and GSTs are listed in Table 3.
2.1.5. Updates on the nuclear receptor-mediated regulation of
xenobiotic-metabolizing enzymes
The human nuclear receptors comprise a family of 48 ligand-
regulated transcription factors that in turn regulate target genes
involved in metabolism and other physiological functions. Some of
these receptors (e.g., peroxisome proliferators-activated receptor
(PPAR), liver X receptor (LXR), hepatocyte nuclear factor (HNF))
are of particular interest in regard to drug metabolism and disposi-
tion as they have been found to regulatemanyXMEs in recent years.
PPARa induces the expression of CYP4A in response to a
heterogeneous group of peroxisome proliferators. PPARg also
regulates the expression of CYP4V2, a fatty acid metabolizing
enzyme, in human tetrahydropyranyl 1 (THP1) macrophages60.
LXR controls the transcription of Cyp7a1 and Cyp27a1, Cyp3a11
and Cyp2e161e63.
Traditional transcriptional factors can bind directly to specific
DNA sequences and thus control the gene expression. However,
epigenetic regulation like histone modification and DNAmethylation modulates transcription of UGTs or CYPs mainly by
changing chromatin architecture. For example, the UGT1A gene
can be repressed by the recruitment of histones in females64.
Several studies determined that microRNAs (miRNAs), could
down-regulate the expression of metabolizing enzymes, which
will be further reviewed in Section 2.3.
In summary, the expression and activity of metabolizing
enzymes can be regulated by multiple factors, including drugs,
nuclear receptors, gene polymorphisms, and even ethnic cate-
gories. Non-P450 enzymes and other conjugative metabolizing
enzymes have gained attention in drug metabolism in recent
years. It is desirable to illustrate the key factors responsible for
variable expression and activity of drug metabolizing enzymes,
as it may be beneficial in the prediction of potential thera-
peutics, drugedrug interactions, and in modifying the PK of
drugs.
2.2. Transporters in the control of PK
2.2.1. Introduction of transporters
Transporters are membrane-bound proteins expressed on the cell
membrane in most tissues with varying abundance. They can
transport a variety of endogenous or exogenous substrates (such as
drugs and their metabolites) in and out of cells. For drugs,
transporters are the gatekeepers for cells and control the uptake
and efflux of drugs. Transporters are involved in the ADME
process of drugs. Therefore, transporters play critical roles in the
pharmacokinetics, efficacy and toxicity of drugs. Alteration of
transporter function or expression may significantly change the
blood and/or tissue exposure of drugs, leading to significant
changes in pharmacokinetics. Furthermore, the induction or in-
hibition of transporters by co-administered drugs can change PK
and pharmacodynamics of therapeutic drugs and produce DDI.
There are more than 400 membrane transporters belonging to
two major superfamilies: adenosine triphosphate (ATP)-binding
cassette (ABC) and solute carrier (SLC) transporters. They utilize
the energy that is released by ATP hydrolysis or an electro-
chemical ion gradient to translocate drugs across the membrane.
2.2.1.1. The ABC family of drug transporters. ABC trans-
porters mainly act as exporters and pump drug molecules out of
cells by utilizing the energy released by the hydrolysis of ATP.
According to the organization and sequence of ATP-binding do-
mains, 49 ABC transporters are classified into seven subfamilies:
ABC1/ABCA, multidrug resistance (MDR)/TAP/ABCB, MRP/
ABCC, ALD/ABCD, OABP/ABCE, GCN20/ABCF and White/
ABCG65. Among them, P-glycoprotein (P-gp, MDR1, ABCB1),
MRPs/ABCCs, breast cancer resistance protein (BCRP/ABCG2)
and bile salt export pump (BSEP/ABCB11) are recognized for
their importance in drug disposition66. P-gp, which is expressed at
a high level in the intestine, liver, kidney, brain and placenta, is the
most studied ABC transporter. Many substrates of P-gp including
antibiotics, statins, immunosuppressants, anticancer drugs and a
broad spectrum of drugs overlap with the substrates of CYPs. The
expression of P-gp is regulated by several transcription factors
including PXR, CAR, vitamin D receptor (VDR) and CCAAT/
enhancer binding protein (C/EBP) and some microRNA such as
miR-451, miR-27a and miR-14567,68. Furthermore, P-gp is usually
overexpressed in cancer cells and plays a critical role in MDR. For
example, during chemotherapy, P-gp may be an obstacle for drug
exposure if the therapeutic drugs are P-gp substrates69. Besides its
Table 2 Endogenous and exogenous substrates of UGTs and ligands of transcription factors.
Family Enzyme Endogenous substrate Xenobiotic substrate Transcription factor
UGT1A UGT1A1 Bilirubin, estradiol, fatty acids SN-38, leonurine, bergenin, axitinib CAR, PXR,
PPARa, AhR43,
NRF2
UGT1A3 Bile acid, arachidonic Polyaromatic amines, non-steroidal anti-inflammatory drugs,
statins, ahydroxygenkwanin, genkwanin, ursolic acid44,
fimasartan45, alpinetin23
PPARa, HNF1,
AhR, LXR, PXR
UGT1A4 Eicosanoids Imipramine, lamotrigine, clonazolam, deschloroetizolam,
etizolam, flubromazolammetizolam
HNF1, PPARa,
PXR, CAR, AhR,
HNF1a
UGT1A6 Serotonin 1-Naphthol 4-nitrophenol AhR, CAR, PXR,
PPARa
UGT1A7 Unknown Icaritin, carcinogens AhR, HNF1,
HNF4a, NRF2
UGT1A8 Fatty acids Retinoids, catechol estrogens, opioids, coumarins, flavonoids,
anthraquinones, phenols, raloxifene
HNF1, HNF4a,
AhR, NRF2
UGT1A9 Steroids, fatty acids Bulky phenols, propofol, mycophenolic acid, niflumic acid,
psoralidin
CAR, HNF1,
HNF4a, PPARa,
AhR, NRF2
UGT1A10 Estrogens Nitrosamine, flavonoids, polycyclic aromatic hydrocarbons,
raloxifene, dopamine
HNF1a, HNF4a,
AhR, NRF2
UGT2A UGT2A2/3 Hyodeoxycholic acid Tobacco carcinogen HNF1, LXR
UGT2B UGT2B4 Arachidonic acid Naftopidil, deoxynivalenol PPARa, AhR, FXR
UGT2B7 Sex-steroid hormones,
glucocorticoids,
mineralocorticoid, bile acids
Naftopidil, deoxynivalenol, mirabegron, efavirenz, zidovudine,
codeine, morphine
HNF1a46, CAR,
PXR, FXR,
PPAR, NRF2
UGT2B10 Eicosanoids Amitriptyline, imipramine, clomipramine, trimipramine CAR, FXR, AR
UGT2B11 Unknown 3a-Hydroxyandrogens, 3a-pregnanes, Hydroxylestrogens ER, AR
UGT2B15 Sex-steroid hormones Oxazepam, lorazepam, sipoglitazar, bisphenol-A AR, ER, HNF3a,
FXR
UGT2B17 Sex-steroid hormones Coumarins, anthraquinones flavonoids, chlorantraniliprole HNF1a, HNF4a,
HNF3a, AR, ER
UGT2B28 Sex-steroid hormones Unknown ER, AR
UGT3 UGT3 Unknown N-Acetylglucosamine Unknown
UGT8 UGT8A1 Bile acids Unknown LXR
1118 Yuhua Li et al.role in MDR induction, P-gp plays a critical role in pharmacoki-
netics, pharmacology and toxicology. Through pumping multiple
drugs out of cells, P-gp decreases the bioavailability of oral drugs
and increases drug efflux into urine or bile. Furthermore, P-gp also
plays a vital role in the maintenance of the bloodebrain barrier by
pumping drugs or toxins out of the CNS70. Another important
ABC transporter group is the MRP family that consists of 9 MRP
proteins (MRP1eMRP9). Among them, MRP2 is important in
drug pharmacokinetics. MRP2, once known as the canalicular
multispecific organic anion transporter, is highly expressed in
liver, intestine and kidney. Chemotherapeutics such as metho-
trexate, melphalan, and statins are the classical substrates of
MRP2. Since co-expressed in the liver, many liver-enriched
transcription factors such as LXR, farnesoid X receptor (FXR),
HNF and C/EBP regulate the transcription of MRP2. Another
efflux transporter BCRP is a half transporter and is expressed at a
high level in a wide variety of tissues such as intestine, kidney,
liver, testis and brain. BCRP is modulated by the progesterone
receptor B (PRB) and estrogen receptor (ER). Another ABC
family drug transporter, BSEP, is primarily expressed in the liver
and pumps bile acids and non-bile acid drugs such as pravastatin
into bile.
2.2.1.2. The SLC family of drug transporters. The SLC family
consists of 55 gene subfamilies and more than 360 familymembers. SLC transporters mainly utilize the energy stored in the
ion gradients across membranes, but do not depend directly on
ATP hydrolysis71. Several SLC family transporters play important
roles in drug disposition including organic anion-transporting
proteins (OATPs/SLC21/SLCO), organic anion and cation trans-
porters (OATs and OCTs/SLC22), peptide transporters (PEPTs/
SLC15) and sodium-dependent bile acid transporters (NTCP/
SLC10A1). The OATP family consists of 11 members. Among
them, four transporters including OATP1A2 (SLCO1A2),
OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3) and OATP2B1
(SLCO2B1) are involved in drug transport72. OATP1A2 is
expressed in the intestinal epithelium, renal epithelium and brain
capillary endothelial cells, while OATP1B1, OATP1B3 and
OATP2B1 are expressed predominantly in hepatocytes. Statins
and anti-cancer drugs like paclitaxel, sorafenib and methotrexate
are known as the substrates of OATPs. The SLC22 family consists
of 23 members, including OCTs, zwitterion/cation transporters
(OCTNs) and OATs. Among OCTs, OCT1 (SLC22A1) is mainly
expressed in the liver, OCT2 (SLC22A2) is located at a high level
in proximal tubular cells, and OCT3 (SLC22A3) has a broader
expression range. Several drugs have been identified as OCT
substrates including anesthetic drugs, the anti-diabetic drug met-
formin, antidepressants, b-blockers and anti-cancer chemothera-
peutics. Among OATs, OAT1 (SLC22A6) and OAT3 (SLC22A8)
have a broader expression range with the highest expression in
Table 3 Endogenous and xenobiotic substrates for GSTs and SULTs that are also ligands of particular transcription factors.
Enzyme Endogenous substrate Xenobiotic substrate Transcription factor
GSTs Steroids, bilirubin, heme, fatty
acids
1-Chloro-2,4-dinitrobenzene (CDNB), 1,2-dichloro-4-nitrobenzene
(DCNB), 4-nitrobenzyl chloride (pNBC), ethacrynic acid (ETHA),
aflatoxin B1 (AFB1), 4-hydroxynonenal (4HNE), acrolein, N-
acetyl-p-benzoquinone imine (NAPQI), cisplatin, busulfan,
dichloroacetate, cyclophosphamide, azathioprine (AZA)
PXR, CAR,
steroidogenic factor
1 (SF-1), RXR
SULT1 SULT1A1 4-Methylphenol,
iodothyronines
4-Nitrophenol PXR, CAR
SULT1A2 Dopamine, estrogens,
catechol estrogens
4-Nitrophenol, 2-naphthol, naloxone, minoxidil PXR, CAR, FXR,
HNF4a
SULT1A3 Dopamine, norepinephrine,
iodothyronines
6-Hydroxydopamine, hydromorphone
SULT1B1 Thyroxine 3-OHB[a]P,1-naphthol
SULT1C1 Thyroxine N-Hydroxyarylamines
SULT1E1 Iodine thyroxine,
pregnenolone
1-Naphthol, naringenin, genistein,
4-hydroxytamoxifen
SULT2 SULT2A Dehydroepiandrosterone
(DHEA), bile acid,
cholesterol, estrone
Tibolone, budesonide
SULT2B Dehydroepiandrosterone
(DHEA), bile acid,
cholesterol, estrone
3b-Hydroxysteroids
Current trends in drug metabolism and pharmacokinetics 1119kidney, while OAT2 (SLC22A7) is primarily expressed in the
liver. OAT1 substrates include antiviral drugs, antibiotics, diuretics
and angiotensin-converting enzyme (ACE) inhibitors. For the
SLC15 subfamily, PEPT1 and PEPT2 are the most studied
transporters. Both mediate oligopeptide uptake. PEPT1 is highly
expressed in the intestine and mediates drug absorption, while
PEPT2 is mainly expressed in kidney and affects renal
reabsorption.
2.2.2. Transporters are critical for PK
The ADME process determines the blood and tissue concentration
of drugs, as well as subsequent pharmacological or toxicological
effects. The intestine and liver, both of which tightly regulate the
entry of drugs into the blood circulation, are important organs in
determining the bioavailability of oral drugs. Elimination of drugs
or their active metabolites occurs either by metabolism to inactive
metabolites that are excreted, or by direct excretion of drugs or
active metabolites in the kidney. The transporters expressed in
intestine, liver and kidney are involved in the absorption, distri-
bution and excretion processes of drugs, and are the major
determinant in blood and tissue concentration of drugs.
2.2.2.1. Transporter-mediated oral drug absorption. Oral drug
absorption primarily occurs in the intestine, which is the major
determinant of drug bioavailability, together with the first-pass
extraction in the liver. Drug molecules pass through the mem-
branes in the intestine through two pathways: passive diffusion
and transporter-mediated absorption.
The process of transporter-mediated oral drug absorption
consists of two parallel transport processes including transporter-
mediated uptake and transporter-mediated efflux73,74 (Fig. 1A). In
general, net drug absorption depends on multiple uptake and
efflux transporters in the intestine. Uptake transporters such as
OATP2B1, PEPT1 and sodium-dependent bile acid transporter
(ASBT/SLC10A2) are involved in the intestinal uptake of drugs
across the brush border membrane75. For example, PEPT1 trans-
ports di/tripeptides-like anticancer drugs such as bestatin and b-lactam antibiotics into enterocytes76e78. Efflux transporters
expressed on the brush border membrane of the intestine, are
considered as the barriers for intestinal drug absorption. P-gp,
MRP2 and BCRP are three major efflux transporters in the in-
testine. P-gp, the most studied efflux transporter, has broad sub-
strate specificity and significantly limits the bioavailability of
many oral drugs79. For example, co-treatment with verapamil, a P-
gp inhibitor, increases the intestinal absorption of afatinib or
bestatin due to P-gp inhibition in the intestine80,81. On the con-
trary, rifampin, a P-gp inducer, decreases the oral absorption of
cyclosporine and tacrolimus through the induction of P-gp in the
intestine82. BCRP is another efflux transporter expressed in the
intestine and suppresses the intestinal absorption of drugs83. Due
to only one ATP binding site and six putative transmembrane
helices, BCRP is considered a “half-transporter”. The substrates of
BCRP include statins (pitavastatin, rosuvastatin), antiviral drugs
(lamivudine, zidovudine, abacavir), anticancer drugs (metho-
trexate, SN-38, irinotecan, gefitinib, imatinib, erlotinib) and anti-
biotics (nitrofurantoin, ciprofloxacin)84. The efflux transporter
MRP2 is also expressed on the brush border membrane of the
intestine and transports a variety of substrates conjugated with
sulfate, glutathione and glucuronide, as well as various unmodi-
fied drugs. Previous studies showed that resveratrol inhibited
MRP2 and thereby increased the intestinal absorption of
methotrexate85.
2.2.2.2. Transporter-mediated drug distribution. Transporters
also affect the tissue distribution and contribute to the selective
distribution of drugs to specific tissues. For example, OATP1B1
and OATP1B3 are the major uptake transporters in the liver for
cilostazol, and MRP2, BCRP, P-gp pump cilostazol out of the liver
into bile86. These transporters assist the liver-specific distribution
of cilostazol. Another example is pravastatin, which enters into the
liver through OATP1B1 and OATP1B3. After being excreted into
the bile, pravastatin is reabsorbed in the intestine to the portal vein
and taken up by the liver, and effectively undergoes enterohepatic
circulation87. Therefore, the liver concentration should be higher
1120 Yuhua Li et al.than that in the circulating blood, leading to a high pharmaco-
logical effect at a relatively low plasma concentration. Trans-
porters are also expressed on the bloodebrain barrier and play
critical roles in restricting the distribution of drugs into the brain.
Increasing evidence has demonstrated that P-gp on the
bloodebrain barrier can suppress the distribution of drugs into the
CNS88,89. Also, BCRP is recognized as an efflux transporter on the
bloodebrain barrier suppressing drug entry into the brain. Except
for efflux transporters, uptake transporters are also expressed on
the bloodebrain barrier and play key roles in the uptake of
neuroactive drugs. OAT3 is highly expressed on the basolateral
membrane of brain capillaries90, and OCT2 is expressed in neu-
rons and the choroid plexus. OCT2 is involved in the reabsorption
of many drugs such as serotonin, norepinephrine, dopamine,
choline and histamine from the cerebrospinal fluid.Figure 1 Drug transporter expression in tissues. Drug transporter
expression in the intestine (A), liver (B) and kidney (C). The arrows
indicate the general directions in which the substrates are transported.2.2.2.3. Transporter-mediated drug excretion. Drug elimina-
tion primarily occurs in the liver and kidney. Hepatobiliary elimina-
tion processes can be summarized as follows: (1) the uptake of drugs
into hepatocytes via uptake transporters or passive diffusion; (2) drug
metabolism in hepatocytes including CYP metabolism (phase I
metabolism) and conjugation (phase II metabolism); (3) excretion
from hepatocytes into bile or portal blood via efflux transporters.
Hepatobiliary transport of drugs is attributable to transporters located
on the basolateral (sinusoidal) or canalicular (apical) membrane of
hepatocytes (Fig. 1B). SLC superfamily transporters are responsible
for drug uptake from the portal blood into hepatocytes. Among them,
OAT2, OCT1, OATPs and NTCP are major uptake transporters.
Efflux transporters such as P-gp, BCRP, MRP2 and BSEP are
responsible for the hepatobiliary excretion of drugs and their me-
tabolites. In addition, the efflux transporter MRP3, 4 and 6 expressed
on the basolateralmembrane are responsible for the basolateral efflux
of drugs from the liver into the blood circulation. The hepatic trans-
porters OAT2, OATP1B1/1B3 and OCT1 are highly expressed in the
liver and are considered to be of particular importance for hepatic
drug elimination, PK and efficacy. Much like the interplay of trans-
port andmetabolic enzymes at the intestinal barrier, these transporters
also have a “gatekeeper” function in the drug movement from the
blood into hepatocytes; they regulate both the number of drugs
available for metabolism by liver enzymes and the subsequent biliary
excretion. Efflux transporters including P-gp, BCRP, MRP2 and
BSEP are responsible for the biliary excretion of endogenous and
exogenous molecules. Many studies have shown that P-gp transports
amphiphilic cationic drugs such as doxorubicin, digoxin and
vinblastine into bile91. BCRP is involved in the biliary excretion of
sulfated conjugates of steroids and drugs such as doxorubicin,
mitoxantrone and daunorubicin, while BSEP transports drugs
including vinblastine and taxol, et al. Due to their important roles in
hepatobiliary efflux, the inhibition of BSEP, BCRP and MRP2 may
lead to cholestasis. Therefore, the effects of chemicals on transporter-
mediated hepatobiliary excretion must be determined in drug
discovery92.
The kidney is the major organ of drug excretion. Renal
clearance of drugs consists of glomerular filtration, tubular
secretion and reabsorption. The proximal tubule region is
responsible for the active secretion and reabsorption of drugs.
Many transporters are located at the renal tubular epithelial cells
and are involved in the proximal tubular secretion and reabsorp-
tion (Fig. 1C). These transporters include OCTs, OATs, multidrug
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phosphate transporter (NPT/SLC17A1), OATPs and PEPTs, as
well as equilibrium and concentration nucleoside transporters
(ENTs and CNTs/SLC28A). Among them, OCTs, OATs and
MATEs play critical roles in the active secretion of renal proximal
tubule. These transporters work in concert with efflux transporters
to transfer drugs into urine. OATs mainly transport anionic drugs
such as beta-lactam antibiotics and anti-inflammatory drugs. The
competitive inhibition of OATs may lead to a decrease in renal
tubular secretion and an increase in the systemic concentration of
drugs. For example, co-administration of probenecid, one OAT
inhibitor, decreases renal secretion, leading to an increase in the
plasma concentration of bestatin93. JBP485, a dipeptide with po-
tential protective activity against kidney, liver and intestinal injury,
has been demonstrated to be a substrate of OATs. Co-
administration of JBP485 and cephalexin decreased the accumu-
lative renal excretion and renal clearance of both compounds77.
When JBP485 and lisinopril were co-administered, the competi-
tive inhibition of OAT1 and OAT3 were also observed in OAT1/3-
HEK293 cells94. In addition, acyclovir, an antiviral drug, was also
a substrate of OAT1/3 and JBP485 can inhibit its renal excretion95.
Furthermore, the DDIs between JBP485 and entecavir through the
competitive inhibition of OAT1 and OAT3 significantly decreased
the renal excretion of both compounds96. On the other hand, OATs
are involved in drug-related nephrotoxicity. Probenecid, by
inhibiting OAT1 and OAT3, reduced the accumulation of cepha-
loridine and subsequently nephrotoxicity97,98.
Three OCT isoforms including OCT1, OCT2 and OCT3 have
been found in the kidney. Among the three OCTs, OCT2 is the
major transporter for renal secretion of a variety of drugs such as
memantine, metformin and amantadine. DDIs may also occur
through the competitive inhibition of OCTs. For example, through
inhibiting OCT2, cimetidine decreases the renal excretion of
metformin and increases its plasma concentration99. On the other
hand, OCT2, by modulating the exposure of drugs to renal
proximal tubule cells regulates the nephrotoxicity of anticancer
drug cisplatin and its analogs100. Substrates taken up from the
systemic circulation may subsequently undergo efflux across the
brush border membrane of proximal tubule cells by various ABC
efflux transporters such as P-gp and BCRP. For example, a probe
P-gp substrate, methotrexate, is actively secreted into urine. Co-
treatment with bestatin, another P-gp substrate, increases plasma
concentrations and decreases the renal clearance of metho-
trexate101. MATE1 and MATE2-K are expressed on the brush
border membrane of proximal tubular cells. MATE1 mediated the
renal secretion of fluoroquinolones including gatifloxacin, cipro-
floxacin, levofloxacin, enoxacin, pazufloxacin, norfloxacin and
tosufloxacin.
In summary, the expression and activity of transporters can be
regulated by drugs and competitive inhibition may occur after co-
administration of more than one drug. Furthermore, species dif-
ferences in transporters complicate pharmacokinetic scaling from
preclinical species to humans. Additionally, the expression of
transporters may also be regulated by disease progression102.
Modulation of transporter expression by disease states can
potentially modify the PK of drugs.
2.3. ncRNAs in the regulation of drug metabolism and
pharmacokinetics
ncRNAs are genome-derived RNAmolecules that are not translated
into proteins. Indeed, the human genome is comprised of over 95%of noncoding sequences103 that are transcribed into various forms of
functional ncRNAs including miRs, transfer RNAs (tRNAs), ribo-
somal RNAs (rRNAs), small nucleolar RNAs (snoRNAs), and long
noncoding RNAs (lncRNAs). Among them, miRNAs usually lead
to translation inhibition or enhance mRNA degradation in cells
through complementary base pairing with target transcripts. Many
miRNAs have been shown to modulate the expression of drug-
metabolizing enzymes or transporters, and consequently alter
cellular drug metabolism and transport capacity, as well as drug
responses (see recent reviews104e106). For instance, miR-27b re-
duces CYP1B1 protein expression in human carcinoma cells and
thus suppresses CYP1B1 enzymatic activity, as indicated by a
P450-Glo™ luminescent assay107. Meanwhile, miR-27b modulates
CYP3A4 expression through direct targeting of CYP3A4 3ʹ-un-
translated region (3ʹUTR) and “indirect” targeting of transcriptional
factors such as NR1I1/VDR108, which may significantly alter
CYP3A4-mediated drug metabolism109,110. Furthermore,
miR-27a/b regulates the expression of a number of transporters
such as ABCB1/P-gp111e113, and thus influences intracellular drug
accumulation and chemosensitivity. In addition, a number of Phase
2 drug-metabolizing enzymes such as the UGTs are regulated by
miRNAs at the posttranscriptional level114e119. Findings on
miRNA-controlled regulation of DMPK provide new insights into
mechanisms behind inter-individual variations in pharmacotherapy.
Recent studies on miRNA regulation in DMPK also led to the
development of novel research approaches and technologies. For
example, while the luciferase reporter assay, gene mutagenesis
and correlation analysis are helpful methods for the assessment of
the interactions between miRNAs and target transcripts, a more
direct approach has been established which is based on the change
of RNA mobility after binding to miRNA, namely RNA electro-
phoretic mobility shift assay (EMSA)120,121. Using this RNA
EMSA and other methods, a number of CYP genes (e.g.,
CYP2C19, CYP2E1 and CYP2D6) and regulators have been
shown to be regulated post-transcriptionally by particular
miRNAs121e125. It is also noteworthy that miRNA research is
limited to the use of miRNA-expressing plasmids or viruses, or
chemically-synthesized or chemo-engineered miRNA mim-
ics126e128. To better capture the properties of biologic RNA
molecules and cellular miRNA machinery, a novel RNA bioen-
gineering technology has been established for the production of
biologic miRNA agents in living cells109,129e133. With such novel
bioengineered miRNA agents produced cost effectively and on a
large scale, extensive functional studies have been conducted and
the results showed rather a modest change in the PK of major CYP
probe drugs in mouse models134. Further studies have demon-
strated the utility of miRNAs as therapeutics or sensitizing agents
for the treatment of human diseases in various animal
models133,135e139.
There is also growing evidence that lncRNAs may regulate the
expression of drug-metabolizing enzymes and transporters. For
example, expression of HNF1a antisense RNA 1 (HNF1a-AS1)
and HNF4a antisense RNA 1 (HNF4a-AS1) shows a significant
influence on the basal and drug-induced expression of drug-
metabolizing enzymes in human cells140. H19, an lncRNA high-
ly expressed in liver tissues, induces the expression of efflux
transporter P-gp/MDR1/ABCB1 in drug-resistant HepG2 cells141.
The lncRNA MRUL confers the overexpression of ABCB1 in
drug-resistant gastric cancer cells142. Furthermore, some studies
have demonstrated that a lncRNA modulates drug sensitivity
through its action on miRNA-transporter axis143,144. In addition,
as RNA editing and posttranscriptional modifications are critical
1122 Yuhua Li et al.for RNA stability and biological function, very recent studies have
also demonstrated the alteration of DMPK gene expression
following RNA editing145e147. Future studies in these areas will
undoubtedly advance our understanding of RNA-based regulation
in DMPK.
In summary, research on miRNA-controlled regulation of
DMPK provides new insights into understanding the post-
transcriptional regulatory mechanisms behind inter-individual
variations. Novel technologies and research approaches are also
established during the investigation of ncRNA regulation of
DMPK gene expression, which should have broad impact on
biomedical research. Evidence is accumulating that some
lncRNAs may be involved in the regulation of DMPK, which
represents a new area of research.3. Drugedrug interactions
3.1. Current status of research on drugedrug interactions
DDIs may result in favorable or toxic effects. Patients frequently
use more than one medication at a time. Depending on the clinical
settings and the number of drugs prescribed, the incidence of
potential DDIs ranges between 15% and 80%148. DDIs can be
classified mechanistically into 3 major types: physio-chemical
incompatibility, PK interactions, and pharmacodynamic in-
teractions149. Physio-chemical interactions usually occur when
positively and negatively charged compounds are mixed before
they are administrated or absorbed. Pharmacokinetics-based
DDIs, characterized by altered concentration of unbound drugs
that exert pharmacological effects, can be caused by several
mechanisms, including: 1) alteration of drug metabolizing en-
zymes (e.g., CYPs)150, 2) alteration of transporters involved in the
absorption, distribution and excretion of drugs (e.g., MDR1, OAT,
OCT, etc)150, 3) influence on plasma protein binding affinity149,
and 4) changes in the function of organs (e.g., gut motility or
stomach content pH)149. Pharmacodynamics-based DDIs are
characterized by a shift of the unbound drug concentration versus
response curve149. New responses that are not present when either
of the drugs is given alone may also be observed when drugs are
used in combination.
In vitro, in vivo and clinical studies are usually conducted to
identify any potential DDIs. The in vitro studies are usually simple
systems that can be used for high throughput screening and provide
mechanistic information for potential DDIs. In vivo animal studies
are often conducted using clinically relevant dosages and pharma-
codynamic endpoints to confirm the in vitro observations. If evi-
dence obtained from in vitro and in vivo animal models suggests
strong DDIs potential further clinical trials are recommended150,151.
Recently, mathematical modeling, particularly physiologically-
based pharmacokinetic (PBPK) modeling has also been applied to
investigate potential pharmacokinetic-based DDIs. A recent review
by Min et al.152 depicted how pharmacokinetic modeling improves
and simplifies the investigation on DDIs. In addition, systematic
reviews and databases summarize all the experimental and predicted
data on DDIs, which are useful for providing warning and proper
advice to patients in clinical practice153.
Although DDIs between small molecule drugs have been well
investigated and documented, knowledges on interactions between
drugs and herbs, interactions between therapeutic biologics, andinteractions mediated by the gut microbiome are currently not
well understood. The cutting-edge investigations on these aspects
are briefly introduced in the following sections.
3.2. Current status of research on herbedrug interactions
Herbal plants and herbal products are commonly used as remedies
and dietary supplements. When herbs are concurrently adminis-
tered with drugs unrecognized herbedrug interactions (HDIs) may
lead to side effects and toxicity. HDIs basically share the same
mechanisms as DDIs. To avoid physio-chemical interactions be-
tween herbal components and drugs, it is usually recommended
that herbs should be taken at two hours before or after the drugs.
Moreover, herbs may sometimes alter the PK and/or pharmaco-
dynamics of the concurrently administered drugs. PK and phar-
macodynamic interactions have been reported between herbs and
drugs with narrow therapeutic indexes, especially drugs for CNS
and cardiovascular diseases154. For example, St John’s wort
(Hypericum perforatum) was reported to decrease warfarin plasma
concentrations via inducing the activity of CYPs, leading to the
loss of anticoagulant activity155. A traditional Chinese herb
Danshen (Salvia miltiorrhiza) was reported to interact with
warfarin on both its PK profiles and pharmacodynamic effects,
resulting in over-anticoagulation and increased risk of bleeding155.
Investigation of HDIs is often more complicated than those of
DDIs, due to the complex herbal components and the batch-to-batch
variation of herbal products. As demonstrated in Table 4, compared
with DDIs, research on HDIs is still insufficient. In vitro screening
assays, which are efficient ways for detecting potential DDIs, may
not be applicable for testing crude herbs or herb extracts, due to the
fact that some of the herbal componentsmay not be bioavailable, and
adding such herbal components to the in vitro cell/microsome sys-
tems may alter results. By using LCeMS/MS, several multi-
compound pharmacokinetic studies allowed the simultaneous
detection of the plasma/tissue concentrations ofmultiple components
after ingestion of the studied herb, facilitating the discovery of the
bioavailable active components and subsequent in vitro and in vivo
mechanistic studies on potential HDIs156,157. Most of the reported
HDIs are based on in vitro and in vivo animal models, providing
evidence with low clinical relevance. Moreover, many clinical
studies were conducted among healthy populations, where the
impact of the herbs on the pharmacodynamics effects of the con-
current drug may not be determined. On the other hand, the wide
variation between different batches of herbal products also leads to
poor reproducibility of the tests. Although not true in all countries,
herbal products in China are generally regulated and used as medi-
cine with standardization of the content of the major active compo-
nents, and the herbal products are sometimes investigated not only as
the effector but also as the affected agent of HDIs. In addition to
experimental approaches based on the pre-clinical and clinical data,
mathematical models have been established to predict HDIs,
demonstrating the feasibility of using PBPK modeling for the pre-
diction ofHDIs152. For example, PBPKmodeling of twomajor active
components from Wuzhi capsule (Schisandra sphenanthera extract)
predicts its interaction with tacrolimus metabolism by CYP3A4 in-
hibition158. However, the application of modeling and simulation on
the investigation of HDIs is still restricted by the limited human
pharmacokinetic data of herbal components152. More sophisticated
designs of clinical studies are warranted to evaluate the safety and
efficacy of the concomitant use of herbs and drugs.
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Therapeutic biologics include therapeutic proteins, monoclonal
antibodies (mAbs), vaccines, and peptide and nucleic acid de-
rivatives that are manufactured for pharmaceutical uses159.
Development of therapeutic biologics is growing fast, and in
clinical practice the risk of DDIs with biologics is increasing.
3.3.1. PK of therapeutic biologics
The PK of biologics is different from those of small molecules.
Since most therapeutic biologics undergo rapid degradation in the
gastrointestinal tract after oral administration, alternative routes,
such as intravenous, intramuscular, and subcutaneous injection
are often used for drug delivery159e161. The distribution of
therapeutic biologics is mainly mediated by interstitial penetra-
tion, lymphatic drainage, transcytosis, and receptor-mediated cell
uptake159e161. Therapeutic proteins usually have a limited vol-
ume of distribution and do not bind to plasma proteins, and their
biliary and renal excretion is generally negligible162. Catabolism
via proteolytic degradation is the predominant clearance pathway
for most therapeutic proteins159e161, while target antigen-
mediated disposition also plays a role161. Moreover, fragment
crystallizable receptor (FcR)-mediated antibody recycling by
monocytes, macrophages, and dendritic cells is a salvage
pathway that prolongs the half-lives of many mAbs159e161. Im-
mune responses participate in both the catabolism and the anti-
body recycling process, and therefore immunogenicity can
significantly influence the clearance of therapeutic proteins159. A
recent review by Ferri et al.162 has summarized theTable 4 Comparison between investigations on DDIs and HDIs151,1
Type of investigation DDIs
In vitro studies  Commonly used for the screening of p
DDIs.
 Provide mechanistic information.
In vivo animal studies  Drugs tested in clinically relevant dos
 Provide pharmacokinetics and pharm
namics information for clinical trials.
Clinical studies  Retrospective evaluation may not
sufficient precision to assess DDIs.
 Clinical trials on healthy volunte
pharmacokinetics-based DDIs.
 Pharmacodynamics-based DDIs and p
toxicity studies on intended patient
populations.
Simulation and
modeling
 PBPK modeling has been extensively
to pharmacokinetic-based DDIs with c
mechanisms.
 Modeling and simulation are recomme
regulatory agencies5.
Systematic reviews
and databases
 A number of databases on DDIs analy
been developed based on solid clinica
evidence.pharmacokinetic DDIs of therapeutic antibodies. Unlike thera-
peutic proteins, nucleic acid and peptide drugs160 are rapidly
eliminated by peptidases and nucleases159,163, and may also un-
dergo slow renal excretion161. Plasma binding of these oligomers
can sometimes be very high and has been reported to affect their
distribution and clearance160.
3.3.2. Pharmacokinetics-based interactions of therapeutic
biologics
Direct competition between therapeutic biologics and small mol-
ecules in PK is not common due to their distinct pharmacokinetic
pathways163. However, certain indirect pharmacokinetic DDI may
occur. Immunosuppressive agents may decrease the immunoge-
nicity of the therapeutic protein so as to hinder its clearance163.
For example, concomitant treatment with the immunosuppressant
methotrexate can decrease the clearance of mAbs including
golimumab164, adalimumab162, and infliximab165. Another indi-
rect pharmacokinetic DDI mechanism is cytokineeCYP modu-
lation. Several biologics with immunomodulatory effects may
alter CYP activities via modulating the cytokine levels leading to
the altered PK of co-administered small molecules that are sub-
strates of the affected CYPs159,163,166. For instance, tocilizumab,
which can induce CYP3A4 activity by decreasing interleukin 6
levels, was found to reduce simvastatin systemic exposure167.
Similarly, by triggering inflammation, influenza vaccination has
been reported to decrease CYP activity and thus influence the
systemic exposure of CYP substrates such as clozapine168. PBPK
modeling is a powerful tool for the investigation of
pharmacokinetic-based interactions between therapeutic biologics53.
HDIs
otential  Single component/artificial mixture of major
components used in a test.
 Does not account for bioavailability.
 Provide mechanistic information for certain
components.
es.
acody-
 Crude herbs or herb extracts tested in clinically
relevant doses.
 Address bioavailability of the herbal
components.
provide
ers for
otential
 Most of HDIs evaluation are retrospective and
are based on cases reports.
 Limited clinical trials and often carried out on
healthy volunteers.
 Lack of monitoring of pharmacokinetic pro-
files of the herbal components.
 Lack of pharmacodynamics and potential
toxicity in patient populations.
applied
omplex
nded by
 Only a few herbal products have been pre-
dicted of HDIs by PBPK modeling.
 Limited human pharmacokinetic data and lack
of herbal standardization restrict the applica-
tion of modeling and simulation on prediction
of HDIs.
sis have
l
 Few databases on HDIs have been established.
 No sufficient clinical data to support the
effectiveness and safety of the combination.
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titatively predict DDIs of CYP-modulating protein drugs (such as
blinatumomab and sirukumab) and small molecule CYP substrates
in patients169,170. On the other hand, pharmacokinetic interaction
between two therapeutic biologics has seldom been reported.
However, such pharmacokinetic DDIs may occur due to specific
binding between two biologics. For example, palifermin is a
truncated form of the endogenous fibroblast growth factor which
contains the heparin-binding domains. Co-administration of pal-
ifermin with heparin was found to increase the systemic exposure
to palifermin up to 5-fold171.
3.3.3. Pharmacodynamics-based interactions of therapeutic
biologics
Comparing to the pharmacokinetics-based DDIs of therapeutics
biologics, their pharmacodynamics-based DDIs are more
commonly reported. A large volume of cases has demonstrated
pharmacodynamic interactions among various hormones owing to
their complex signaling networks159. For instance, insulin can
interact with numerous drugs including hormones, antidiabetics,
antibiotics, antipsychotics, etc172. Recombinant growth hormones
interact with small molecule hormones such as glucocorticoids,
estrogens, thyroxin, etc.159. Although co-administration of bi-
ologics indicated for the same disease usually results in additive or
synergistic efficacy, co-administration may also induce toxicity.
Both anakinra and etanercept are approved for the treatment of
rheumatoid arthritis. However, combined use of the two biologics
led to severe adverse effects including increased risk of infection
and increased neutropenia without significant improvement in
therapeutic efficacy173.
3.3.4. Risk assessment for DDIs of therapeutic biologics
Due to the distinct pharmacokinetic and pharmacodynamic
properties of therapeutic biologics, the classic approach for DDIs
prediction for small molecules may not applicable for therapeutic
biologics. With the increase in therapeutic biologics in the market,
it is critical to call for building strategies and regulations on the
potential DDIs involving biologics. Based on the current findings
on the major mechanisms for the pharmacokinetic-based DDIs of
therapeutic biologics, assessment of the modulation of CYP ac-
tivities and immunogenicity are recommended. In terms of
pharmacodynamics-based DDIs, identification and monitoring of
clinical endpoints relevant to both the efficacy as well the adverse
effects of therapeutic biologics is highly recommended.
3.4. Trends in microbiota mediated drugedrug interactions
Recent studies have indicated that the microbiota is a vital drug
target in many disease treatments. Many therapeutics have great
effects on altering the composition of the microbiota. As indicated
in Fig. 2A, changes in microbiota in the gastrointestinal tract may
influence the metabolism of co-administered drugs, leading to
altered pharmacokinetics. Findings have shown that gut micro-
biota can mediate drug metabolism including reduction174,
oxidation175, dehydroxylation, decarboxylation176, etc. DDIs be-
tween antibiotics and drugs that are metabolized by gut microbiota
are commonly reported. Many antibiotics can disturb the PK of a
co-administered drug by affecting the enzymatic activities and
composition of gut microbiota177, leading to an altered therapeutic
effect. For example, the coagulant drug sulfinpyrazone can be
metabolized to sulfinpyrazone sulfide in the gut contents. It was
found that the plasma pharmacokinetic profile of sulfinpyrazoneand sulfinpyrazone sulfide was changed in patients treated with the
antibiotic metronidazole178. After reduction via azoreductases in
gut microbiota, prontosil was metabolized to sulfanilamide, which
exhibits potent antibacterial activities. In addition, it was noted in
rats that the conversion of prontosil to sulfanilamide can be sup-
pressed by antibiotics, leading to the reduced antibacterial ef-
fects174,179. Most recently, gnotobiotic mouse models and PBPK
models have been established to untangle host and microbial
contributions to the pharmacokinetic profile180. These novel
experimental and computational strategies can be incorporated in
future investigations on microbiota-mediated DDIs.
In addition to effects on pharmacokinetics, altered microbiota
composition may also lead to pharmacodynamics changes in the
concomitant drugs (Fig. 2B). It was noted that the presence of a
certain type of bacteria may have an impact on chemotherapy and
immunotherapy181,182. Clinical trials are currently conducted on
microbiota interventions, such as probiotics and fecal microbiota
transplant (FMT), to explore their influence on the efficacy and
toxicity of co-administrated chemotherapeutic agents, immuno-
therapeutic agents and anti-inflammatory drugs183. The potential
benefits of probiotics and FMT to increase the efficacy of pem-
brolizumab in the treatment of PD-1 resistance patients184 and to
reduce the adverse effects of aspirin185 and irinotecan186 are
currently under clinical investigation.
Besides well-known influences on the microbiota from antibi-
otics and probiotics, influences from other types of drugs or natural
products are very limited. Although evidence of gut microbiota-
mediated DDIs remain limited, the growing interest in microbiota
will definitely provide a better understanding on their influence on
the PK and pharmacodynamics of drugs. Nevertheless, the impact
of herbal medicine on the gut microbiome is unavoidable, and such
research is expected to provide more in-depth understanding on
herbedrug interactions. In summary, in addition to consideration of
classical PK and pharmacodynamic interactions, microbiota-
mediated drugedrug/herbedrug interactions are expected to
bring additional insight into their therapeutic effects.
3.5. Summary
Investigation of herbedrug interactions (HDIs) is often more
complicated than that on DDIs, due to the complex herbal com-
ponents and the batch-to-batch variation of herbal products. More
pharmacokinetic and pharmacodynamic data on the bioavailable
herbal components from clinical studies using standardized herbal
products are warranted for better understanding of HDIs. With the
increasing number of therapeutic biologics in the market, it is
critical to build strategies and regulations on the potential DDIs
involved biologics. Based on the current findings on pharmaco-
kinetic- and pharmacodynamic-based DDIs of therapeutic bi-
ologics, assessments on the modulation of CYP activity and
immunogenicity, and identification and monitoring of clinical
endpoints of the therapeutic biologics is recommended. In addi-
tion to consideration of classical PK and pharmacodynamics in-
teractions, microbiota-mediated HDIs/DDIs are expected to bring
additional insight into their interactions. Novel experimental and
computational strategies, such as gnotobiotic animal models and
physiologically-based pharmacokinetic modeling can be incor-
porated in future investigations on microbiota-mediated HDIs/
DDIs.
In summary, the incidence of interactions between various
therapeutics is high in patients taking multiple drugs and dietary
supplements. Although DDIs between small molecule drugs are
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fully explored. It is essential to develop efficient strategies for the
investigation of the interactions between drugs and herbs, and
between therapeutic biologics. Furthermore, the growing knowl-
edge on the microbiota as therapeutic targets and as a site of drug
metabolism leads us to pay more attention to microbiota-mediated
interactions when examining potential DDIs and HDIs.
4. Diseaseedrug interactions
Understanding diseaseedrug interactions is clinically important
due to the risk of treatment failure and the incidence of adverse
reactions. An accumulation of strong research evidence indicates
that diseaseedrug and drugedisease interactions can have a pro-
found effect on the response to a medication, yet most of the
existing results are only from animal models. Moreover, there are
differences between animal disease models and human dis-
eases187. Differences between different species should be also
taken into account. In recent years PBPK modeling has gradually
been applied to the prediction of diseaseedrug interactions188,57.
However, further clinical study or real-life experience is needed to
justify results from PBPK modeling. Additionally, the potential
mechanism of diseaseedrug interactions remains poorly charac-
terized. Therefore, further studies are also needed to reveal the in-
depth and comprehensive mechanism involved in diseaseedrug
interactions.
In recent years, apart from the DDI, diseaseedrug interactions
have attracted lots of attention due to their potential impact on
efficacy and safety of clinical therapy. Diseaseedrug interactions
mainly refer to the disease itself can lead to changes in PK and
pharmacodynamics of drugs, and also include the influence of
alteration of endogenous substrates related to metabolism on
disease status. Both effects of disease on drug metabolism and
effects of metabolism regulation on diseases have the potential to
increase the risk of treatment failure and the incidence of adverse
reactions189. Although there have been some reports published onFigure 2 Microbiota-mediated pharmacokinetic and pharmacodynamic
effect supported by obtained evidence, and the dotted arrow indicates potdiseaseedrug interactions, there are still many unknown issues to
be characterized. This review provides an update on the research
on diseaseedrug interactions and offers an in-depth perspective on
new strategies for the elucidation of diseaseedrug interactions.
4.1. Effects of diseases on drug metabolism
Disease is a vital factor affecting clinical medication. Disease
changes the PK of a drug by altering the ADME process; on the
other hand, disease can also change the sensitivity of the body to
drugs by altering the number of receptors and their function in or-
gans. Clinical practice should take into account the effects of a
disease on a drug for the best therapeutic outcome and to avoid
serious adverse reactions by adjusting the dose, the interval of
administration, and the route of administration, etc. Current prog-
ress on disease effects on drug metabolism are listed in Table 5.
4.1.1. Effects of diabetes on drug metabolism
Diabetes mellitus, commonly referred to as diabetes, is a group of
metabolic disorders in which there are high blood sugar levels
over a prolonged period. Diabetes mellitus is also a well-known
risk factor for cardiovascular disease and atherosclerotic compli-
cations, especially coronary heart disease209. In recent years there
have been many reports of the effect of diabetes on drug meta-
bolism. Alterations in function and expression of ABC trans-
porters at the bloodebrain barrier in diabetes have been
observed210; for instance, it was found that the uptake of
vincristine by cultured rat brain microvessel endothelial cells
incubated in diabetic rat serum were higher than uptake in
nondiabetic rat serum, which was related to the impairment of P-
gp function and expression at the bloodebrain barrier of diabetic
rats190. Moreover, in brain cortex, STZ-induced diabetes mellitus
may induce an impairment of function and expression of BCRP.
The uptake of prazosin and cimetidine, two typical substrates of
BCRP, was significantly increased in diabetic rats compared to
uptake in non-diabetic rats191. However, different from theinteractions between different drugs. (The solid arrow indicates an
ential effects.)
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betes may enhance MRP2 function and expression in liver, kidney
and intestine, which then leads to increased excretion of sulfo-
bromophthalein (a substrate of MRP2) via the bile, urine and in-
testinal perfusate192. Atorvastatin is a substrate of OATP1B1, an
influx transporter expressed on the sinusoidal membrane of he-
patocytes. Recent studies found that diabetes mellitus could
enhance the hepatotoxicity and decrease exposure to atorvastatin
in rats partly through upregulating hepatic Oatp2193,194.
In addition to Oatp2, upregulation of hepatic Cyp3a also
contributes to the decreased exposure to atorvastatin, simvastatin
and simvastatin acid in diabetic rats193e195. Accumulated evi-
dence shows that diabetes mellitus apparently alters the expression
and activity of cytochrome P450 (CYP450) enzymes196,211. In
diabetic rats, the AUC of theophylline was significantly smaller
than that of normal rats because of significantly faster time-
averaged total body clearance in diabetic rats, which was attrib-
uted to upregulated hepatic CYP1A2 and CYP2E1. Furthermore,
diabetes mellitus could significantly increase exposure (area under
the curve and peak concentration) to glibenclamide after oral
administration. Data with hepatic microsomes suggested the
impairment of glibenclamide metabolism and efflux in diabetic
rats197. Accumulating evidence also has shown that diabetes
increased the metabolism of CYP3A4 substrates by upregulating
the function and expression of CYP3A4 in hepatic cells198.
Interestingly, diabetes mellitus showed a tissue-specific effect on
CYP3A expression and activity (induced in liver and inhibited in
intestine), resulting in opposite pharmacokinetic behavior for
verapamil after oral and intravenous administration to diabetic
rats212. UGTs, the major phase II conjugation enzymes, can also
be affected by diabetes mellitus. It was reported that the UGT1
family is adaptively upregulated in the diabetic gastrointestinal
tract199. Given the essential regulatory role of the gastrointestinal
site in drug disposition, such changes in UGTs may have an
impact on the metabolism of therapeutic drugs and endogenous
substrates.
4.1.2. Effects of liver disease on drug metabolism
There is growing evidence to suggest that many hepatic diseases
can affect drug metabolism. The effect of liver disease on drug
metabolism is mainly due to the alteration of liver hemodynamics
and activity of liver microsomal enzymes. Local and systemic
liver injuries have a major effect on the expression and activity of
DMEs in the liver213. For example, compared to control rats, there
were significant changes in pharmacokinetic profiles after ad-
ministrations of rhubarb anthraquinone-extracts in CCl4-induced
liver-injury rats. The plasma concentrations of the four pharma-
cokinetic markers (Rhein, emodin, aloe-emodin, chrysophanol) of
rhubarb anthraquinone extract increased, which indicated that
their metabolism and excretion changed after liver injury200. Liver
failure is often associated with hepatic encephalopathy, due to
dyshomeostasis of the central nervous system (CNS). One study
showed that the function and expression of P-gp and BCRP
decreased, while the function and expression of MRP2 increased
in the brain of acute liver failure (ALF) mice214. The attenuated
function and expression of P-gp at the BBB might enhance
phenobarbital distribution in the brain and increase phenobarbital
efficacy on the CNS of ALF mice201. In addition, ALF could
enhance oral plasma exposure of zidovudine in rats by down-
regulation of hepatic UGT2B7 and intestinal P-gp202.
Fatty liver disease, also known as hepatic steatosis, is a con-
dition where excess fat builds up in the liver. Previous researchshowed that valproic acid with a high-fat diet-induced fatty liver
could upregulate UGTs and was accompanied by the increased
expression of CAR and PPARa215. Further analysis revealed that
liver disease in warfarin users was associated with a significant
increase in the likelihood of hemorrhage216.
4.1.3. Effects of heart failure on drug metabolism
Heart failure (HF) is considered an epidemic disease in the modern
world affecting approximately 1%e2% of the adult population.
ManyCYPenzymes have been identified in the heart and their levels
have been reported to be altered during HF. There is a great deal of
discrepancy between various reports on CYP alterations during HF,
likely due to differences in disease severity, the species in question
and other underlying conditions. A recent review by Aspromonte
et al.217 has summarized a comprehensive modulation of cardiac
CYP in patients with HF. In general, cardiac CYP1B and CYP2A,
CYP2B, CYP2J, CYP4A and CYP11 mRNA levels and related
enzyme activities are usually increased in HF217,218. On the other
hand, HF plays an important role in the down-regulation of hepatic
CYP involved in drug metabolism through several mechanisms
which include hepatocellular damage, hypoxia, elevated levels of
pro-inflammatory cytokines, and increased production of heme
oxygenase-1219. For example, the plasma concentrations of caffeine
(CYP1A2 probe), mephenytoin (CYP2C19 probe), dextromethor-
phan (CYP2D6 probe) and chlorzoxazone (CYP2E1 probe) were
significantly elevated in patients with congestive HF203. It was
suggested that the doses of these CYP enzymes substrates should be
decreased when used in patients with congestive HF.
4.1.4. Effects of renal disease on drug metabolism
Evaluation of drug metabolism in patients with end-stage renal
disease is important because these patients use a large number of
medications and are at risk of adverse reactions and DDI. Previous
studies found that end-stage renal disease patients had a 50%
increase in the plasma warfarin S/R ratio relative to control sub-
jects. This may be reflective of a selective decrease in hepatic
CYP3A and CYP2C9 activity in renal failure204,205. Furthermore,
results from a “cocktail” approach showed that the enzyme ac-
tivities of CYP3A4 and CYP2C9 of patients with renal failure
were selectively inhibited220. Therefore, if CYP34A and CYP2C9
substrates are used in patients with renal failure, the dose needs to
be lowered. Although chronic renal failure (CRF) has been found
to be associated with a decrease in liver CYP, the mechanism
remains poorly understood. The N-demethylation of erythromycin
was decreased by more than 35% (P < 0.001) in hepatocytes
incubated with serum from rats with CRF221. It is speculated that
the mediator(s) of uremic serum may down-regulate the CYP of
normal hepatocytes. In addition, a recent study investigated the
effects of adenine-induced chronic kidney disease (CKD) in rats
on the activities of some XMEs in liver and kidneys. It was found
that the plasma theophylline concentration was significantly
increased in rats with CKD206. Moreover, a reduced metabolism
of midazolam could be observed in rats with acute kidney injury
(AKI)207.
4.1.5. Effects of sepsis on drug metabolism
Sepsis is the systemic inflammatory response syndrome caused by
infection, which is a common complication following surgery,
especially abdominal surgery, with higher mortality. It has been
well documented that hepatocellular dysfunction occurs early in
sepsis and contributes to multiple organ failure and ultimately
death222. Among them, the effects of polymicrobial sepsis on the
Table 5 Summary of the effects of specific diseases on drug metabolism.
Type of diseases Affected drugs Related mechanisms
Diabetes mellitus  Vincristine and other P-gp substrates: increased
uptake190.
 Prazosin, cimetidine and other BCRP substrates:
increased uptake191.
 Sulfobromophthalein and other MRP2 substrates:
enhanced excretion192.
 Atorvastatin, simvastatin: decreased exposure193e195.
 Theophylline: increased metabolism196
 Glibenclamide: inhibited metabolism and decreased the
efflux197.
 CYP3A4 substrates: increased metabolism198.
 UGT1 substrates: increased metabolism199.
 Impairment of P-gp function and expression.
 Impairment of BCRP function and expression.
 Induction of MRP2.
 Upregulated OATP2, CYP3A.
 Induction of CYP1A2 and CYP2E1.
 Inhibition of CYP2C11 and BCRP.
 Upregulated CYP3A4.
 Upregulated UGT1.
Liver disease  Rhein, emodin, aloe-emodin, chrysophanol: inhibited
metabolism200.
 Phenobarbital: enhance distribution201.
 Zidovudine: inhibited metabolism and decreased the
efflux202.
 MRP2 substrates: enhanced efflux201.
 Inhibition of CYP and UGT metabolism.
 Inhibition of P-gp and BCRP (brain).
 Down-regulation of UGT2B7 and P-gp.
 Induction of MRP2 (brain).
Heart failure  Caffeine and other CYP1A2 substrates: inhibited
metabolism203.
 Mephenytoin and other CYP2C19 substrates: inhibited
metabolism203.
 Dextromethorphan and other CYP2D6 substrates:
inhibited metabolism203.
 Chlorzoxazone and other CYP2E1 substrates: inhibited
metabolism203.
 Down-regulation of CYP1A2.
 Down-regulation of CYP2C19.
 Down-regulation of CYP2D6.
 Down-regulation of CYP2E1
Renal disease  Erythromycin and other CYP3A substrates: inhibited
metabolism204.
 Warfarin and other CYP2C9 substrates: inhibited
metabolism205.
 Theophylline and other CYP1A1 substrates: inhibited
metabolism206.
 Midazolam and other CYP3A11 substrates: inhibited
metabolism207.
 Inhibition of CYP3A.
 Inhibition of CYP2C9.
 Inhibition of CYP1A1.
 Inhibition of CYP3A11.
Sepsis  CYP1A1 substrates: inhibited metabolism208.
 CYP1A2 substrates: inhibited metabolism208.
 CYP2E1 substrates: inhibited metabolism208.
 Down-regulation of CYP1A1.
 Down-regulation of CYP1A2.
 Down-regulation of CYP2E1.
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attracted considerable attention due to their potential
diseaseedrug interactions in clinical therapy. It has been reported
that the major hepatic CYP isoforms CYP1A1, 1A2, 2B1, 2E1
were down-regulated during polymicrobial sepsis208,203e224.
Moreover, results from mechanistic studies show that nitric oxide
(NO) and the AhR play key potential roles in down-regulation of
hepatic CYP during sepsis225,226. Therefore, treatment with
pharmaceutical agents that regulate or are metabolized by CYP
enzymes might be approached cautiously in the septic patient.
On the other hand, early and appropriate antimicrobial treat-
ment is the predominant intervening measure to decrease patient
mortality227. However, the pathophysiologic changes during sepsis
such as systemic capillary leak syndrome, altered shift of body
fluid and hypoalbuminemia can lead to changes in pharmacoki-
netics/pharmacodynamics (PK/PD) parameters such as apparent
volume of distribution (Vd)
228 and clearance (CL)229 that affect the
achievement of PK targets and increase the risk of treatmentfailure with routine dosing. In addition, it is likely to cause low
blood protein symptoms in sepsis due to the increased capillary
permeability, decreased hepatic albumin synthesis and a large
number of infusions230. Therefore, the effect of hypoalbuminemia
on antibiotic PK also cannot be ignored. It is crucial to reduce
patient mortality by adjusting antimicrobial doses and improving
drug infusion to optimize antimicrobial therapy according to the
characteristics of PK/PD during sepsis.
4.2. Effects of endogenous metabolism mediated by nuclear
receptors on diseases
In recent years the regulation of endogenous metabolism mediated
by nuclear receptors on diseases has received increasing attention
with improvements in bioanalytical technology, especially the
intervention of the various “omics”. Among them, PXR and CAR
are two closely related and liver-enriched nuclear hormone re-
ceptors originally defined as xenobiotic receptors. However, an
1128 Yuhua Li et al.increasing body of evidence suggests that PXR and CAR also have
endobiotic functions that impact glucose and lipid metabolism, as
well as the pathogenesis of metabolic diseases. PXR and CAR not
only regulate the transcription of drug-metabolizing enzymes and
transporters, but also orchestrate energy metabolism and immune
responses231. The cutting-edge investigations on these aspects are
briefly shown in Table 6.
A recent study revealed that PXR ablation inhibited high-fat
diet-induced obesity, hepatic steatosis, and insulin resistance232.
These results may help to establish PXR as a novel therapeutic
target, and PXR antagonists may be used for the prevention and
treatment of obesity and type 2 diabetes. PXR was also reported to
play a vital role in maintaining biliary bile acid homeostasis by
regulating the biosynthesis and transport of bile salts233. Activa-
tion of the PXR pathway was associated with decreased lith-
ocholic acid-induced cholestasis in mice241. PXR may be
developed as a therapeutic target for cholesterol gallstone disease.
Interestingly, study has revealed a function of PXR in enlarging
liver size and changing liver cell fate by activation of the yes-
associated protein (YAP) signaling pathway. This has implica-
tions for understanding the physiological functions of PXR242. In
addition, PXR plays an important endobiotic role in adrenal ste-
roid homeostasis. Activation of PXR markedly increased plasma
concentrations of corticosterone and aldosterone234. These results
suggest that PXR is a potential endocrine disrupting factor that
may have broad implications in steroid homeostasis and
drugehormone interactions.
CAR has also been increasingly appreciated for its endobiotic
functions in influencing glucose and lipid metabolism, with dys-
regulation implicated in two of the most prevalent metabolic
disorders, obesity and type 2 diabetes243. Further study found that
CAR suppresses hepatic gluconeogenesis by facilitating the
ubiquitination and degradation of PGC1a244. Given the metabolic
benefits of CAR activation, CAR may represent an attractive
therapeutic target to manage obesity and type 2 diabetes.
Nonalcoholic steatohepatitis (NASH) is common and medi-
cally significant because it is closely related to metabolic syn-
drome and has the potential to progress into the more harmful
cirrhosis. Emerging evidence points to an important function of
AhR in the uptake of fatty acids in the liver and the pathogenesis
of fatty liver disease236. Activation of the AhR sensitizes mice to
NASH by deactivating mitochondrial sirtuin deacetylase Sirt3245.
These results suggest that the use of AhR antagonists might be a
viable approach to prevent and treat NASH.
LXRs are known as sterol sensors that impact cholesterol and
lipid homeostasis, as well as inflammation. The hepatic functions
of LXRs are well documented and the pathophysiological role of
LXRs was uncovered progressively in recent years. Activation of
LXR prevents lipopolysaccharide-induced lung injury by regu-
lating antioxidant enzymes and the implication of this regulation
is pulmonary tissue protection237. Moreover, a recent study
demonstrated that activation of LXR attenuates OA-induced acute
respiratory distress syndrome by attenuating the inflammatory
response and enhancing antioxidant capacity238.
FXR, a nuclear receptor mainly expressed in enterohepatic
tissues, is a master regulator for bile acid, lipid and glucose ho-
meostasis246. Emerging evidence indicates that restoration of FXR
protein levels may represent a new strategy for enterohepatic and
metabolic diseases. Hepatitis B virus X protein (HBx) is a hepa-
titis B virus protein that has multiple cellular functions, but its rolein the pathogenesis of hepatocellular carcinoma (HCC) has been
controversial. It was reported that transactivation of FXR by full-
length HBx may represent a protective mechanism to inhibit
HCC247. Additionally, FXR antagonism was also reported to be
pivotal in attenuating obstructive cholestasis in bile duct-ligated
mice235. These results suggest that FXR may be developed as a
therapeutic target for cholesterol gallstone disease.
The tumor suppressor p53 is traditionally recognized as a
surveillance molecule to preserve genome integrity. Recent studies
have demonstrated that it contributes to metabolic diseases. It was
found that the activation of p53 participated in promoting bile acid
disposition and alleviating cholestatic syndrome by up-regulating
the expression of Cyp2b10, Sult2a1 and Abcc2/3/4, which pro-
vides a potential therapeutic target for cholestasis235. In addition,
p53 could attenuate acetaminophen-induced hepatotoxicity by
regulating the CYPs, SULTs and MRPs, which provides a po-
tential new therapeutic target for APAP-induced liver injury248.
Metabolism regulation mediated by downstream targets of the
above transcriptional factors may also play an important role in
diseases. For example, NAD(P)H: quinone oxidoreductase 1
(NQO1) has been reported to be a prognostic biomarker and a
promising therapeutic target for patients with NSCLC due to its
frequent overexpression and significantly increased activity in
NSCLC. It was found that depleting tumor-NQO1 potentiates
anoikis and inhibits the growth of NSCLC239. Furthermore, recent
results from a metabolomics analysis have revealed that inhibition
of cell proliferation upon NQO1 depletion was accompanied by
suppressed glycometabolism in NQO1 high-expression human
NSCLC A549 cells. Also, NQO1 depletion significantly decreased
the gene expression of hexokinase II240.
4.3. Summary
Understanding diseaseedrug interactions is clinically important
due to the risk of treatment failure and the incidence of adverse
reactions. An accumulation of strong research evidence indicates
that diseaseedrug and drugedisease interactions can have a pro-
found effect on the response to a medication, but most of the
existing results are only from animal models. In recent years,
PBPK modeling has also gradually been applied to the prediction
of diseaseedrug interactions57,188. However, further clinical study
or real-life experience is certainly needed to justify the results
from PBPK modeling. Additionally, the potential mechanisms of
diseaseedrug interactions are not well-characterized. Therefore,
further studies are needed to reveal the in-depth and comprehen-
sive mechanism involved in diseaseedrug interactions.
5. Mathematical modeling
The application of mathematical modeling to problems in PK has
a rich history in the form of pharmacokinetic modeling to explore
how simulation can be used to improve our understanding of
common issues not readily addressed in human pharmacology249.
Animal models are mainly used in experimental physiology,
experimental pathology and experimental therapeutics, especially
in the study of new drugs. In the earliest stage of drug discovery/
development, various cell-based models and animal models were
used for the prediction of human PK and toxicokinetics250. In this
section, the current status and future challenges on PBPK
modeling and animal models are summarized.
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As early as 1937251 physiological parameters were introduced into
pharmacokinetic parameter estimation. The term PBPK model
appeared in 1977252. Although the PBPK method was proposed a
long time ago, it was applied to support new drug development in
the last decade since the mechanism of drug metabolism and
transport gained clarity. Two known milestones of extensive
application for industry are: 1) A PBPK review team was set up in
the office of clinical pharmacology (CDER/FDA, US) because of
increasing numbers of PBPK submissions in 2013253; 2) PBPK
guidance was released by FDA254 and EMA255 respectively during
2016e2018. A total of 217 PBPK submissions were reviewed by
the FDA in 2016256. As one of the four major pharmacometric
research methods257, the strategy of waiving clinical trials through
PBPK study has been extensively accepted in western society and
is gradually being accepted in China.
5.1.1. Basic concepts of PBPK
PBPK can be utilized to mechanistically understand and predict
in vivo pharmacokinetic characteristics from a whole body
perspective by integrating system-specific parameters (such as
physiological parameters), drug-specific parameters (such as
physicalechemical and mechanistic pharmacokinetic data), and
specific PBPK model structure258. It can quantitatively describe
drug concentration kinetics in the blood and each tissue through a
series of mathematical differential equations, which allows it to
accurately predict target tissue drug concentration as well as to
understand drug absorption, distribution, metabolism, elimination,
and transportation (ADMET) processes. Because it incorporates
system-specific parameters into equations of each tissue, it can
also be used to predict drug concentration in tissues under
different scenarios, such as co-administration of enzyme inhibitor
or in a specific population (hepatic- or renal-impaired patients,
pediatrics, or elders), which could support new drug development
strategy, clinical trial design, and improved clinical development
efficiency.
5.1.2. PBPK in drug development
5.1.2.1. PK drugedrug interaction study. As of August 2016,
60% of PBPK study cases submitted to FDA were related to
drugedrug interactions (DDI)256. Among the three predominant
DDI mechanisms, enzyme-259, transporter-260, and disease-
mediated DDI261,262, enzyme-mediated DDI cases showed the
best predictive performance in PBPK. Hsueh et al.259 summarized
104 publications with DDI predictions, a total of 126 and 360Table 6 Summary of endogenous substances related to diseases and
Endogenous substance Diseases involved
Glucose and lipid  Obesity and type 2 diab
Biliary bile acid  Cholesterol gallstone233
 Cholestatic syndrome23
Corticosterone and aldosterone  Steroid dyshomeostasis
Fatty acids  Nonalcoholic steatohep
Sterol  Lung injury237
Oleic acid  Acute Respiratory Dist
Hexokinase II  Non-small cell lung cancases were reported for drug as metabolic “victim” and “perpe-
trator” respectively. The predictive performance of CYP3A- and
CYP2D6-mediated DDI was found to be the best for new drugs as
victim using the PBPK method. Two enzymes are involved in
metabolism of large proportion of marketed drugs and well-
established probe perpetrators are available256,263. The predictive
performance was poorer for new drugs as perpetrator259. In order
to accurately predict the quantitative effects of an enzyme inhib-
itor264 or inducer265 on a substrate, the FDA suggested the
following study strategy256,266: a) Develop an initial PBPK model
of enzymeesubstrate based on in vitro data followed by verifi-
cation using human single-dose PK data; b) develop a PBPK
model of inducer or inhibitor and validate its enzyme modulation
effect using in vivo (or literature data) data; c) predict the effect of
inhibitor/inducer on substrate PK characteristics in humans using
the PBPK model, which will support DDI study strategy or clin-
ical trial design, especially for the dose selection; d) if a dedicated
DDI was required and conducted, then the initial PBPK model
will be verified and modified based on observed DDI data; e)
predict other untested scenarios and validate dose selection.
Following this strategy, predictive performance was summarized
in report published by Hsueh et al.259. As stated in submitted cases
to the FDA, AUCR or CmaxR (ratio of AUC or Cmax) was esti-
mated within the range of (0.80, 1.25) and (0.50, 2.00) for higher
than 73% and 77% cases respectively. Although overall DDI of
CYP-mediated interactions could be estimated well, prediction of
time-dependent DDI and intestinal enzyme-mediated DDI was
still challenging256.
Because tissue concentration can indicate efficacy or safety
better than plasma concentration, it is more important to be pre-
dicted, especially for the drugs with a “disconnected” concentra-
tion in tissues compared to plasma concentration, which may be
caused by significantly different distribution through trans-
porters267. Unfortunately, the best prediction method theoretically,
the PBPK method, showed worse predictive performance for
transporter-mediated DDI compared to that of enzyme-mediated
DDI, which was due to ubiquitous tissue distribution, unique
cellular localization, and competing active and passive pro-
cesses268. Furthermore, the lack of knowledge pertaining to dis-
ease- or population-specific factors makes PBPK more
challenging for transporter-mediated DDI prediction. In order to
accurately predict unbound and intra/subcellular drug concentra-
tions while considering the role of a transporter, selecting
appropriate in vitro (such as imaging) and in vivo experimental
methods to determine tissue concentration followed by verifica-
tion of PBPK model in animals may be helpful267. Recently,nuclear receptors.
Related nuclear receptor or protein
etes232  PXR, CAR
,234
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 P53
234  PXR
atitis236  AhR
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renal impairment affecting liver enzymes262. However, research
on disease-mediated DDI are limited, and few PBPK cases to
predict this kind of DDI have been reported269,270, and so further
research to uncover the rationales behind of disease and physio-
logical parameters is needed.
5.1.2.2. Specific population study. One of the most known
characteristics of the PBPK model is that it can integrate drug-
specific and system-specific parameters, which includes age,
gender, disease status, and specific physiological status. This
characteristic allows us to predict PK exposure changes by
mechanistically changing specific parameters according to the
different populations, such as pediatric, elderly, and in patients
with hepatic or renal impairment. However, accurate prediction
for these specific populations is still quite challenging because
changes in system-specific parameters generally are not available
or quantified accurately271. The FDA and other scientists sum-
marized PBPK prediction strategy in patients with renal impair-
ment272 or hepatic impairment273, in the elderly274, pediatric275,
fetal276, and pregnant patients277 but, because of the above limits,
these predictions could be utilized only to aid in clinical trial
design in these specific populations rather than to waive these
dedicated clinical trials without any verification in these specific
populations.
5.1.2.3. Generic drug development. In comparison to the
in vitroein vivo correlation (IVIVC) method the PBPK method was
advantageous because it could identify the contribution of penetra-
tion, intestinal metabolism and transport to the absorptionedrug
concentrationetime curve. Therefore, PBPK analysis can estimate
in vivo dissolution characteristics more accurately, which will be
useful to guide drug development278,279. Therefore, the US FDA
continuously held modeling and simulation workshops to make
PBPK methods more useful in generic drug development280e282 as
well as suggested a research strategy for industry283,284. Additionally,
physiologically-based oral absorption modeling can be utilized to
guide Quality by Design (QbD) and predict food effects, effect of
acid-reducing agents, SUPAC activities, and to influence label lan-
guage. Although it was potentially powerful, its application is still
limited because of physiological information missing in PBPK sys-
tem models. The European OrBiTo (Oral Biopharmaceutical Tool)
Project results showed that less than 50% of drugs could receive 2-
fold error prediction performance using the PBPK modeling
method285. Modified in vitro experiment data with more similarities
to in vivo status and accurate physiological parameters affecting the
rate-limiting absorption processmay be able to improve its predictive
performance.
5.1.2.4. Other applications and trends of PBPK modeling
methods. In addition to the above applications, the PBPK
modeling method also could be used to predict first-in-human PK
profiles286. It may be helpful for those drugs with nonlinear
metabolism characteristics. Recently, a semi-PBPK model (or
minimal PBPK model)287,288 was reported to extensively survey
human biologics PK profiles to assess the predominant clearance
site and dynamically describe system plasma concentrations and
two other virtual compartments, lumped tissues with continuous
and fenestrated vascular endothelium. This semi-PBPK model
structure could allow investigators quickly estimate PBPK pa-
rameters using system drug concentrations considering drug-receptor binding in systems as well as in tissues, as described in
two recent reviews289,290.
The PBPK modeling method is not an independent modeling
method, and sometimes it is better to be integrated with other
modeling methods for better results. In order to understand PK
characteristics in mechanism, allometric scaling291 and in vitroein
vivo extrapolation methods292 can also be used to analyze preclini-
cal data and compare the results with human data, which can provide
more key information from different angles to develop a PBPK
model more accurately indicating the real disposition process in
humans293. Taking advantage of the PBPK ability to predict drug
tissue concentration, a PBPK-PD model could be developed to
capture pharmacodynamic characteristics in a more accurate way
with more understanding of the mechanism294,295, which is helpful
for those drugs with significantly inconsistent exposure between
system and targeted tissues. For a new moiety entity clinical devel-
opment, verification of an established PBPK model based on human
data with the specific ADMET mechanism is required, which may
need an additional clinical trial. Recently, global development is
going to become routine strategy, and ethnic differences in PK
characteristics will be important. Therefore, PBPK could support
evaluation of ethnic differences by its unique contribution to the
mechanistic understanding296. Because population PK (PopPK) is
routinely used to identify the key factors affecting PK profiles fol-
lowed by quantifying these key factors, a PopPK study could verify
PBPK simulations under some extreme scenarios, which may allow
sponsors to waive some dedicated clinical trials (PBPK-PopPK
strategy)297. Under many scenarios, we only pay attention to drug
concentration in tissues related to PK, PD, or safety characteristics,
so we don’t need to accurately capture drug kinetics in other tissues.
Therefore, in order to increase parameter reliability without a
decrease in PBPK power, we could shrink the typical PBPK model
integrating each tissue in humans to a semi-PBPK model integrating
necessary target tissues and replace other tissues with one or two
compartments.
Along with the coadministration of herbal or natural products,
the potential herbedrug interaction is gaining increasing attention,
and can be predicted using a PBPK modeling method. But accu-
rate prediction of herbedrug interactions is still a challenging
mission because of the complex composition and relatively
limited knowledge of individual constituents that produce the in-
teractions. A feasible procedure is to firstly identify the major
constituents followed by compoundecompound interaction pre-
diction as previous introduced158,298. The major concern with this
procedure is to prove that the interaction of major constituents is
similar to that of the whole herb.
5.2. Summary
In summary, PBPK can be utilized to mechanistically understand
and predict a priori in vivo pharmacokinetic characteristics from a
whole body perspective by integrating system-specific and drug-
specific parameters. PBPK modeling has been routinely con-
ducted for new entities to illustrate pharmacokinetic characteris-
tics when drugedrug interactions happen or when dosing in
specific populations needs optimization. The predictive perfor-
mance of CYP3A- and CYP2D6-mediated DDI was found to be
best for new drugs as victim using PBPK method, which could be
applied to waive part of clinical trial. Due to unclear changes in
transporter-mediated mechanism and system-specific parameters
in specific populations, PBPK modeling power is limited to sup-
porting clinical trial design.
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Animal models are mainly used in experimental physiology,
experimental pathology and experimental therapeutics, especially
in the study of new drugs. In the earliest stage of drug discovery/
development, various cell-based models and animal models were
used for the prediction of human PK and toxicokinetics250. The
common laboratory animals for DMPK include rats, rabbits, dogs,
monkeys, etc. However, with the development of gene editing
technology, animal models of special ADME genes are needed to
better study the mechanisms of DMPK, including the metabolic
pathway and its regulatory mechanism.
6.1. Conventional transgenic animal models for DMPK
research
Traditional animal models are constructed by homologous
recombination in embryonic stem cells. This method implements
foreign gene knock-in, but the recombination efficiency is very
low, and the recombinant site has certain randomness299. In 2009,
the discovery and application of nucleic acid engineering enzymes
greatly advanced gene knock-in technology300. Zinc-finger nu-
cleases (ZFNs) are the first nucleic acid engineering enzymes to
be discovered300. They cleave DNA at specific sites to form
double-strand breaks (DSBs), which are then repaired by cell
homology and used as templates by exogenous donor DNA. The
repair of DSBs result in knocking out the foreign gene300. Another
engineering nuclease that was subsequently discovered for gene
editing is transcription activator-like effector nucleases (TAL-
ENs)300,301. Since the 1990s, Cyp knockout (KO) mice have been
successfully constructed using gene KO techniques, such as
Cyp1a2, Cyp2e1, Cyp2c9, Cyp3a4 and Cyp2d6302e305. In recent
years some of mouse models have been used to study the DMPK
of drugs under specific Cyp knockout conditions. To overcome the
differences in subtype composition, protein expression, catalytic
activity and substrate specificity between mouse and human CYP
enzymes, scientists have built humanized animal models to better
evaluate drug metabolism characteristics of human CYPs. For
example, in 2007 humanized Cyp1a1/2 mice were constructed for
a toxicology study306. Humanized Cyp2c19 mice for drug meta-
bolism307, humanized Cyp3a4 mice for drug interactions308, and
humanized Cyp2d6 mice for drug interactions309 were reported in
2008, 2011 and 2012, respectively. In 2012, Cyp2c knockout mice
and Cyp2c9 humanized mice were generated for drug metabolism
and drug interaction studies304. In 2015, humanized Cyp2b6 mice
were also constructed for drug metabolism310.
Both Cyp gene KO and humanized mouse models have been
constructed by traditional knockout techniques, i.e. homologous
recombination of foreign DNA fragments with genes of the same
or similar sequence in the host genome, thus replacing the cor-
responding gene sequences in the genome of the recipient cells
and integrating them into the host. In the cell genome, the key
technologies of this method include the acquisition of embryonic
stem cells, the design of target, and the screening of embryonic
stem cells. Homologous recombination is time-consuming, costly,
as well as inefficient in gene editing, and may lead to adverse
mutations. As it is difficult to obtain and culture embryonic stem
cells in rats, the construction and application of knockout or
knock-in rat models have lagged behind the mouse models. Rats
are a rodent model animal widely used in DMPK and have many
advantages over mice, such as larger size, easy manipulation, high
tolerance to blood volume loss and large sample size. Moreover,rats in certain physiological and pathological states such as dia-
betes and breast cancer, are closer to humans than mice311,312.
Therefore, it is particularly urgent to construct novel rat models of
DMPK-related genes through KO and humanization.6.2. Novel CRISPR/Cas9-based animal models for DMPK
research
The clustered regularly interspaced short palindromic repeat
(CRISPR)/CRISPR-associated 9 (Cas9) system, as the third gen-
eration of artificial nuclease technology, provides a promising tool
for genetic engineering. It offers an efficient approach to develop
genetically modified animal models and a potential strategy for
targeted gene therapies. The CRISPR/Cas9 system allows simul-
taneous digestion of multiple targets at multiple sites in the same
cell, making it possible to knock out or knock in multiple genes.
CRISPR/Cas9 as a new gene editing technology has many char-
acteristics and advantages, including high targeting accuracy,
simultaneous knockout of multiple sites of target genes, simplicity
of operation and no species restriction. In recent years, CRISPR/
Cas9 has been applied to the study of drug absorption, disposition,
metabolism and excretion, as well as the preparation of ADME
animal models.
Today CRISPR/Cas9 technology enables DMPK scientists to
develop better and more predictable ADME models in vitro and
in vivo, especially to study ADME genes that have not been fully
explored previously. Most published papers of CRISPR/Cas9-
mediated ADME describe CYP drug metabolic enzymes and
ABC drug transporters. For example, in 2016, the rat Cyp2d gene
locus (containing Cyp2d1-5) was knocked out and replaced with
human CYP2D6 in Wistar rats, but a functional characterization
was not reported313. In the same year the rat Cyp2e1 gene was
knocked out in Sprague Dawley rats, and the KO rats were
physiological normal and lost the expression and function of the
CYP2E1 enzyme314. In 2017, Cyp3a1 and Cyp3a2 double KO rats
were generated by CRISPR/Cas9 technology315, and Cyp2c
(Cyp2c6, Cyp2c11 and Cyp2c12) genes were also knocked out in
rats316. Finally, Cyp2c11 gene was knocked out in Sprague
Dawley rats317. In vitro and in vivo metabolic studies of the CYP
substrates indicated that the target CYP isoform was functionally
inactive in all KO rats314,315. It should be noted that KO models
resulted in the compensatory regulation of other CYP isoforms
involved in drug metabolism314,315. However, the potential
mechanisms of these compensatory changes remain unclear. In
addition, these KO models showed some differences, such as
changes in serum testosterone concentrations315 or alkaline
phosphatase314. Some of these differences can be attributed to the
deficiency of CYP functions, such as CYP3A-mediated testos-
terone metabolism. Therefore, these physiological changes in KO
rats should be considered when comparing ADME data from KO
models with data from wild-type rats. In addition to the rat KO
models, a Cyp2b9/10/13 KO mouse model was also generated via
CRISPR/Cas9 technology318. It is interesting that there were no
significant compensatory changes in other CYP isoforms in Cyp2b
KO mice, which may be due to low CYP2B hepatic expression,
especially in male mice318. In 2019, a novel MDR1 (Mdr1a/b)
double-knockout rat model was generated in Sprague Dawley rats
by the CRISPR/Cas9 technology319. The loss of MDR1 function
significantly increased digoxin uptake in Mdr1a/b/ rats. The
MDR1 KO rat model is of great significance to study the function
of MDR1 in drug transport, toxicity and drug resistance.
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In summary, genome editing based on CRISPR/Cas9 has been
identified as a breakthrough technology in constructing animal
models. Novel animal models are not only conducive to the basic
research of human diseases, but also can be used to study the
molecular mechanisms of drug pharmacodynamics, toxicity and
clinical use. Furthermore, DMPK animal models will promote the
study of DMPK mechanisms and strengthen the relationship be-
tween drug metabolism and pharmacology/toxicology. For
example, the potentials and mechanisms of DDI between erlotinib
and docetaxel was studies by using Cyp3a1/2 KO rats320. Doce-
taxel significantly increased the maximum concentration and
systemic exposure of erlotinib in wild type (WT) rats, but the DDI
was significantly attenuated in Cyp3a1/2 KO rats, suggesting that
the CYP3A plays the perpetrating role of docetaxel on erlotinib.7. Non-classical xenobiotic metabolic pathways
Drug metabolism or drug biotransformation is the process by
which xenobiotics are enzymatically modified to make them more
readily excretable and eliminate pharmacological activity. Drug
metabolism is the prominent process in drug disposition. Under-
standing the metabolic fate and the corresponding enzymes are
important with regard to metabolite toxicity and drugedrug
interaction risks. Detailed data from drug metabolism studies aid
in the drug clinical practice and drug design and modification.
Over the past decades the basic mechanism and rules of drug
metabolism, especially mediated by CYP, have been clarified. The
strategies and approaches used for drug metabolism investigations
have come to maturity and industrialization. Recently, with the
rapid development of the separation technology and qualitative
techniques, such as IMS-TOF/MS or novel 2D NMR technology,
and the considerable amount of attention directed at non-CYP
enzymes, several undesirable drug metabolites have been identi-
fied, and novel metabolic reactions were discovered. Some
outwardly rational reactions are newly described based on the
novel understandings of the mechanism underlying common
biotransformations. This section briefly reviews a series of cases
of novel metabolic reactions and pathways to provide readers new
insights into investigations on drug metabolism.
7.1. Oxidative pathways
Oxidative pathways, including sp3-hybridized C-hydroxylation,
unsaturated C-oxidation, N-dealkylation/deamination, O-deal-
kylation, S-dealkylation, N-oxidation, S-oxidation, and oxidative
cleavage of esters and amides classified by functional groups are
the most common biotransformations. In recent years some un-
expected oxidative reactions or pathways have been reported.
Aromatic ring-containing drugs are most common and gener-
ally metabolized by P450-mediated p-electron oxidations to form
an arene-epoxidized intermediate. The latter undergoes a hydride
shift spontaneously to produce stable phenol metabolite(s).
However, for some specific structures, unstable epoxides are
preferentially attacked by nucleophilic substances, thereby leading
to reactive intermediate-related covalent attachments. For
example, for cocaine, the covalent adducts of biological thiols are
first characterized321. In vitro investigations revealed that
CYP1A2, 2C9, and 2D6 catalyze the formation of a reactive
epoxide intermediate from the oxidation of the cocaine phenylmoiety (Fig. 3A). Although an aryl moiety is generally considered
a stable functional group, epoxide ring opening is attacked by
nucleophilic thiolates, such as N-acetylcysteine or glutathione, for
cocaine.
Carbonecarbon cleavage and formation reactions are rare in
xenobiotic metabolism. Recent studies have focused on the roles of
flavin-containing monooxygenases (FMOs) to catalyze unexpected
BaeyereVilliger oxidations,which is a kind of carbonecarbon bond
cleavage reaction. E7016, a potential anticancer agent with a 4-
hydroxypiperidine moiety was confirmed to be a substrate of
FMO5322. The generation of the major ring-opened hydroxyl-
carboxylate metabolite was proposed by a three-step reaction, as
follows: dehydrogenation of the secondary alcohol on the parent
drug to form piperidine-4-one, followed by insertion of an oxygen
atom to form a lactone via the BaeyereVilliger oxidation, and
further CEs-mediated hydrolysis. Recently, the 2,3-dihydropyridin-
4-one (DHPO) ring in MRX-I (an analog of the antibiotic linezolid)
was also reported to undergo a similar carbonecarbon cleavage
reaction in humans323. However, different from piperidine-4-one,
BaeyereVilliger oxidation of the DHPO ring forms an enol lactone
and is further hydrolyzed to an enol, which can be transformed to an
aldehyde intermediate by enolealdehyde tautomerism. The alde-
hyde intermediate underwent either oxidation catalyzed by short-
chain dehydrogenase, aldehyde ketone reductase, and aldehyde
dehydrogenase (ALDH) or reduction mediated by ALDH to
generate the observed directed DHPO ring-opening metabolites
MRX459 or MRX455-1, respectively (Fig. 3B). H2
18O experiments
were conducted to elucidate the mechanism underlying the forma-
tion of the two metabolites.
7.2. Reductive metabolic pathways
The majority of in vivo biotransformations are oxidation, while
reductive reactions preferentially occur in anaerobic or low-O
conditions. A considerable number of the same enzymes that
catalyze oxidative metabolism, such as P450s, aldo-keto reduc-
tase, carbonyl reductase, xanthine oxidase, aldehyde oxidase, and
quinone oxidoreductase, can also be involved in reductions. Under
the catalysis of some specific enzymes or the involvement of
reducing agents, some uncommon reductive metabolic pathways
are observed.
NADPH-cytochrome P450 reductase (POR) and cytochrome-
b5 is crucial for P450 electron transporter chain integrity because
they donate electrons to P450s from NADPH. Thus, most mar-
keted recombinant P450 enzymes generally contain cytochrome-
b5 and POR to enhance their oxidative efficiencies. In some cases,
POR alone can also catalyze one-electron reduction, such as with
aristolochic acid324. Another reported substrate of POR is an
aldehyde intermediate (M-CHO) that is formed during the meta-
bolism of imrecoxib, which is a moderate COX-2 inhibitor325.
POR expresses dual effects on further M-CHO metabolism,
namely oxidation to form carboxylic acid metabolite (M2) and
unexpected reduction to form a hydroxymethyl metabolite (M1),
by donating electrons to P450s or competitively to the substrate,
respectively (Fig. 4A). The two opposite metabolic pathways,
especially M-CHO reduction, led to an underestimation of the
amount of M2 in static in vitro incubations.
7.3. Hydrolysis pathways
Many drugs with specific functional moieties, including esters,
amides, thioesters, epoxides, sulfates, and glucuronides can be
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by the corresponding enzymes, such as esterase or amidases.
Prodrug design has received increasing interest, thereby leading to
considerable attention to the important roles of hydrolytic meta-
bolism. Some novel hydrolytic enzymes also catalyze undesirable
reactions.
For example, arylacetamide deacetylase (AADAC) is a serine
hydrolase expressed in human liver and intestine that is rarely
reported compared with other hydrolytic enzymes (CEs and par-
axonase). Only one AADAC isoform is present in humans.
AADAC is identified as a lipase that is capable of hydrolyzing
endogenous cholesterol ester326; however, it has been recently
found to be responsible for some clinical drugs, such as prasu-
grel327 and vicagrel328. Different from clopidogrel, the thiolactone
metabolite of vicagrel is formed via a rapid hydrolysis before
intestinal absorption329. The first activation step for vicagrel was
initially believed to be mediated only by human intestine CES-2
(CES2) until a recent finding showed that AADAC also contrib-
uted to vicagrel hydrolysis (Fig. 4B). The activation of the parentFigure 3 Cases of some unusual metabolic pathways of oxidation, inclu
adduction, and (B) BaeyereVilliger oxidation mediated by FMO5.drug before entering the systemic circulation guarantees short
onset time and avoidance of “clopidogrel resistance” attributed to
CYP2C9 gene polymorphisms.
Another case of hydrolytic enzymes newly identified is
dipeptidyl peptidases (DPPs), which can catalyze the hydrolysis
of cyanopyrrolidine DDP-4 inhibitors. Generally, a nitrile group
in the drug structures prevents metabolism because of its well-
known inertness, and as a result, a nitrile moiety is increasing
introduced as a block on metabolically labile sites in drug
design330. However, for vildagliptin, anagliptin, and besigliptin
(not saxagliptin), the biotransformation of the nitrile group into
carboxylic acid is the major metabolic pathway in vivo by the
DPP family such as DPP-4, DPP-2, DPP-8, DPP-9, and fibroblast
activation protein-a331. Among them, DPP-2 has the highest hy-
drolytic capacity after DPP-4. However, other substrates con-
taining a nitrile group, such as lacosamide and flutamide, cannot
be hydrolyzed by DPPs probably because the nitrile moiety in
these structures cannot be positioned in the catalytic triad of Asp-
His-Ser of DPPs.ding: (A) proposed mechanism for cocaine metabolism to thiol-related
Figure 4 Instances of some unusual metabolic pathways for reduction, hydrolysis, and conjugation, including: (A) formation mechanism for
M1 and M2, the major imrecoxib metabolites in humans, (B) hydrolysis pathways of vicagrel in humans, and (C) Nþ-glucuronidation of
morinidazole.
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Generally, conjugation pathways involve the addition of an
endogenous hydrophilic group to a drug or its metabolite(s),
including glucuronidation, sulfation, glutathione conjugation,
amino acid conjugation, acetylation, and methylation. Conjuga-
tion generally introduces polar groups to facilitate drug excretion,
except for methylation and acetylation. Although this finding is
true for many cases, several unusual conjugative reactions were
reported in recent years.
The substrates for glucuronidation generally have an OH (i.e.,
alcohols, phenol, and carboxylic acids), amino (i.e., aliphatic
tertiary amine, aromatic primary amine, and sulfonamide) or thi-
ophenol group. In general, for drugs possessing both tertiary
amine and hydroxyl groups, O-glucuronidation is always formed
preferentially over N-glucuronidation. However, a reversible
regioselectivity is observed in the conjugative metabolism of
morinidazole in humans, where glucuronidation prefers the ter-
tiary nitrogen of the morpholine ring to the aliphatic hydroxyl
group at the side chain of morinidazole (Fig. 4C)332. Additionally,
molecular modeling studies indicated that the regioselectivity for
morinidazole glucuronidation is unrelated to steric hindrance.
UGT1A4, as well as UGT1A3 and 2B10, are often considered
enzymes that play important roles in Nþ-glucuronidation333e335.
However, according to the morinidazole experience, UGT1A9 can
be identified as a new UGT isoform specializing in tertiary
aliphatic amine N-glucuronidation.
In addition, several novel conjugates, including carnitine
conjugation to cyclopropanecarboxylic acid336 creatinineconjugation to andrographolide337, and phosphoethanolamine
conjugation to pimasertib338, recently have been discovered. The
combination or further modification of the common conjugation
process has been also reported339,340.
7.5. Summary
In recent years there has been an increased effort to better un-
derstand the role of enzymes beyond P450, UDP-
glucuronosyltransferase, and aldehyde oxidase in drug meta-
bolism. Recently, several biological enzymes responsible for
endogenous substrate catalysis, such as dipeptidyl peptidases and
arylacetamide deacetylase, are newly proven to have additional
capabilities in drug transformation. Drugs that rely on these non-
P450 enzymes for their in vivo clearance, however, usually un-
dergo non-classical metabolic pathways. The basic mechanism
and rules of drug metabolism cannot be characterized based on the
structures of the drugs alone, because the presence of metabolic
intermediates that would allow for the intra-molecular rear-
rangement are likely factors in unusual metabolite formation. This
subtle but potentially significant hypothesis suggests that the
electron or radical-mediated modulation of biotransformation
characteristics may represent uncommon underlying mechanisms
for undesirable metabolic pathways, with relevant toxicological
consequences.
Several novel and unusual reactions and pathways have been
reviewed. Most of these reactions are attributed to (I) metabolic
intermediate formation and rearrangement and (II) the involve-
ment of novel metabolic enzymes, especially non-P450s.
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analytical instrumentation, as well as the introduction of modern
approaches in drug metabolism investigation, new metabolic re-
actions continue to be discovered. Accurately predicting drug
metabolism in an empirical manner and clarifying the metabolism
mechanisms responsible for drug adverse reactions and
drugedrug interactions will increase in the future. Additionally,
valuable inspiration may be provided for rational drug design and
modification with the expansion of metabolic enzymes, many of
which are recognized as new therapeutic targets.8. Conclusions and perspectives
DMPK research is essential for understanding the efficacy and
safety of medications. Integrated studies on drug-metabolizing
enzymes and transporters underlying the ADME processes as well
as their transcriptional and posttranscriptional regulation mecha-
nisms provide a comprehensive understanding of interindividual
variations in pharmacotherapy. Future studies in these areas will
undoubtedly advance our understanding to achieve better predic-
tion of PK properties. Understanding the DDIs and diseaseedrug
interactions is clinically important as such interactions may in-
crease the risk of adverse reactions or lead to treatment failure.
Although DDIs between small molecule drugs are relatively well-
characterized, other potential interactions are not fully explored,
including interactions with herbal biologics and other new forms
of therapeutics. Furthermore, more attention should be paid to the
microbiota-mediated drug interactions when examining potential
DDIs and HDIs. There is emerging evidence indicating that
diseaseedrug interactions can have a profound impact on the
therapeutic outcomes. Further studies are needed to reveal the
critical mechanisms by which diseaseedrug interactions are pro-
duced. While the benefits of PBPK are obvious for clinical trials,
it is better to integrate PBPK with other modeling methods and
consult experimental findings to design clinical trials in support of
new drug development. Novel animal models such as those
created through CRISPR-Cas9-based gene editing techniques
should be an invaluable addition to current tools for PK studies.
With the application of sensitive and accurate analytical in-
struments and technologies, many new metabolic reactions and
biotransformation pathways have been and will be discovered.
Predicting drug metabolism more accurately and clarifying the
metabolic mechanisms responsible for adverse drug reactions and
DDIs will become possible in the future. Collectively, DMPK
research awaits further innovation and mechanistic studies while
DMPK remains a critical component in drug development, and is
essential for practicing precision medication.
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